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ABSTRACT

Oligodendrocytes (OL)s are the dominant cell type in the white matter and
are

integral

for

synaptic

transmission

essential

for

proper

neuronal

communication between brain areas. Previous studies have shown that
intravenous administration of the mononuclear fraction of human umbilical cord
blood (HUCB) cells in rat models of stroke reduced white matter injury, gray
matter injury and behavioral deficits. Yet the mechanisms used by HUCB cells
remain unknown in ischemic injury. These studies will investigate both in vitro
and in vivo approaches to elucidate this mechanism in OLs. When mature
primary OLs were coincubated with HUCB cells, HUCB cells secreted soluble
factors that reduced cell death in OLs exposed to OGD. Microarray analysis
revealed that HUCB cell treatment induced OL gene changes. These changes
included genes involved in cell proliferation, signaling, anti-oxidant activity, and
myelination. To extend these findings, the middle cerebral artery occlusion
(MCAO) model was used to assess the expression profile of protein products of
gene changes observed in vitro. The in vivo data mirrored in vitro data in that
metallothionein 3 (Mt3), peroxiredoxin 4 (Prdx4), myelin oligodendrocyte
glycoprotein (Mog), U2AF homology kinase 1(Uhmk1), and insulin induce gene
1(Insig1) were upregulated in OLs of the white matter tract adjacent to the infarct.
Furthermore,

double

immunofluorescence staining
ix

determined

that

OLs

expressed these proteins. Other reports have shown that HUCB cells secrete
soluble factors related to cellular protection, including interleukin 6 (IL-6),
interleukin 8 (IL-8), and interleukin 10 (IL-10). Other factors are known for their
proliferative actions, such as vascular endothelial growth factor (VEGF), BDNF,
platelet derived growth factor B (PDGF-B), leukemia inhibitory factor (LIF), and
granulocyte colony stimulating factor (GCSF) all of which converge on the Akt
survival pathway. Given these findings we hypothesize that Akt activation is
integral to HUCB cell mediated OL protection. In models of excitotoxicity, the
addition of Akt inhibitor IV blocked HUCB cell mediated protection in OL cultures
exposed to 24 hrs OGD. In vivo, HUCB cell treatment increased Akt activation,
antioxidant protein expression and decreased caspase 3 cleavage in the external
capsule in a time dependent manner. The next series of experiments determine
whether the soluble factors secreted by HUCB cells could replace HUCB cells as
treatment. LIF expression is increased in HUCB cells as compared to peripheral
blood and as previously mentioned, LIF is secreted by HUCB cells. Additionally,
LIF

rescued

OLs

from

spinal

cord

and

experimental

autoimmune

encephalomyelitis injury. Thus LIF was investigated. LIF protected OL subjected
to 24 hr OGD, increased antioxidant Prdx4 gene expression and reduced
reactive oxygen species production. Additionally the inclusion of Akt inhibitor IV
blocked LIF induced OL protection. Similar results were obtained when GCSF
was evaluated. All these findings indicate that HUCB cell mediated OL/white
matter protection is due to the soluble factors secreted by the mononuclear
population of these cells. These soluble factors including LIF activate cellular

x

machinery leading to enhanced cellular survival. Here we found a specific
survival pathway activated by soluble factors released from HUCB cells, leading
to Akt activation. Akt activation arrests stroke induced apoptosis and reduced the
expansion of the infarct, promoting functional recovery from acute ischemic
injury.

xi

CHAPTER ONE
INTRODUCTION

D.D. Rowe, MS, A.E. Willing, PhD, K.R. Pennypacker PhD.

1

Overview of Stroke
Each year an estimated 780,000 Americans will experience an initial
ischemic event, and over 150,000 of these individuals will succumb to
complications as a direct result of the stroke (Association 2008). According to the
American Heart Association, stroke is the third leading cause of death in the
United States. The high incidence of stroke places an enormous financial burden
on the American health care system, an estimated $69 billion yearly (LloydJones, Adams et al. 2009). Therefore the development of effective therapeutics
to reduce stroke related morbidity and mortality will provide both financial and
societal benefits.
Tissue plasminogen activator (t-PA) is currently the only Food and Drug
Administration (FDA) approved treatment for acute ischemia (Pan, Yu et al.
2008). t-PA represents a class of thrombolytic agents which restores blood flow
to ischemic areas by enzymatically dissolving clots, but does not possess
neuroprotective activity. In clinical trials, t-PA treatment within 4 hours of stroke
onset significantly reduced stroke-related morbidities; use beyond this limited
therapeutic time window is ineffective and could prove detrimental (Hacke,
Donnan et al. 2004). As a result, only 3-5% of stroke patients are able to use tPA (Marler and Goldstein 2003; Association 2008). Effective stroke therapies are
clearly needed to extend the therapeutic time window providing treatment for a
larger population of stroke patients.
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Types of Stroke
Ischemic Stroke
The major classifications of stroke are defined as either hemorrhagic or
ischemic. Ischemic strokes account for 83% of all strokes and occur when an
obstruction is present within a vessel supplying blood to the brain (Association
2008; Lloyd-Jones, Adams et al. 2009). Depending on origin and location of the
clot, an ischemic event can be further classified as thrombotic or embolic. With
thrombosis, ischemia develops at the point of the clot, whereas in an embolic
stroke the clot arises from a specific location, travels in the circulatory system
and is lodged in a narrowed vessel (Association 2008). The severity of a stroke is
further based on cerebral blood flow (CBF) downstream the obstructed vessel.
The terms acute, mild, or severe are used to describe the extent of an ischemic
injury. Normal CBF is typically recorded as 45-110 cm3 × 100 g-1 × min-1. An
acute ischemic stroke is marked by immediate depletion of oxygen and glucose
in the affected brain tissue, while mild ischemia is classified as a condition in
which a residual CBF of 11–20 cm3 × 100 g-1 × min-1 is recorded. This reduction
in CBF leads to the activation of reversible apoptotic pathways, the target of
developing therapeutic agents. In severe ischemic events, CBF of ≤ 6 cm3 × 100
g-1 × min-1 is usually recorded; this condition is classically associated with
complete energy loss in affected cells, leading to necrosis (Kaufmann, Firlik et al.
1999). Given that immediate cell death as a result of severe ischemia is not
reversible, neuroprotective agents will not reduce these infarctions, but may
target behavior deficits that result from the ischemic insult.
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Hemorrhagic Stroke
Accounting for 17% of all strokes, hemorrhagic strokes result from
ruptured blood vessels leading to severe bleeding, swelling and compression of
tissue in the affected area. Hemorrhagic strokes are subcategorized depending
on the location of the hemorrhage; intracerebral and subarachnoid hemorrhages.
Intracerebral hemorrhages are the result of ruptured vessels leading to bleeding
within these brain areas, the thalamus, basal ganglia, cerebellum or the pons.
Subarachnoid hemorrhages denote bleeding from a ruptured vessel into the
space between the brain and the skull (subarachnoid space). Hemorrhagic
strokes usually result from weakened blood vessels as a consequence of
aneurysms, head injuries, high blood pressure and arteriovenous malformations
(Association 2008).

Because of the pervasive and devastative nature of

ischemic injury in the current population, this topic will be extensively discussed.

Ischemic Stroke Pathology
Energy Depletion
The brain rapidly metabolizes oxygen and glucose. As a result, immediate
energy depletion occurs following the occlusion of vessels supplying blood to the
brain. Within minutes of energy starvation, cellular ATP synthesis is arrested.
Lack of energy production leads to an imbalanced cellular ion gradient and
cellular excitotoxicity due to membrane depolarization, sodium influx, calcium
influx, and potassium efflux into the extracellular space (Doyle, Simon et al.
2008). These processes trigger the degradation of membranes and proteins
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essential to the maintenance of homeostasis resulting in the outward radiation of
cellular depolarization from the ischemic core leading to calcium accumulation
within cells. Elevated intracellular calcium and sodium increase mitochondrial
reactive oxygen species (ROS) production, cellular reactive nitrogen species
(RNS), free radical production and activation of cell death cascades (Coyle and
Puttfarcken 1993; Doyle, Simon et al. 2008).

Immune Response
Negligible amounts of proinflammatory cytokines are present in the brain
under normal physiological conditions. Energy depletion as a result of ischemia
triggers activation of the immune system. Once activated, the resident central
nervous system (CNS) immune cells, the microglia, secrete cytokines,
chemokines, matrix metalloproteinases (MMP), nitric oxide (NO) and reactive
oxygen species (ROS) creating an environment conducive to the recruitment of
proinflammatory cells (Sharma and Kumar 1998; Wang, Tang et al. 2007).
Recruitment of these cells increases the secretion of proinflammatory mediators
resulting in the disruption of the blood brain barrier, infiltration of peripheral
inflammatory and immune cells such as leukocytes. Microglia along with
peripheral immune cells accumulate in the infarct area where the inflammatory
signal is amplified, exacerbate injury and perpetuate the destructive cycle leading
to the outward expansion of the infarct (Emsley and Tyrrell 2002; Danton and
Dietrich 2003).
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Reperfusion
Stroke pathology is not only a consequence of ischemia which causes
oxygen and glucose deprivation, but also a result of reperfusion. The reperfusion
of an occluded vessel increases cellular ROS. ROS are produced by
dysfunctional mitochondria that generate oxidative stress and release apoptosis
related proteins upon tissue oxygenation. ROS initiate proinflammatory cytokine
and chemokine production by immune cells. In response to proinflammatory
cytokines, inflammatory cells release MMPs, NO and ROS. This reperfusion led
inflammatory response results in blood brain barrier disruption, infiltration of
peripheral immune cells and expansion of the infarct (Emsley and Tyrrell 2002;
Danton and Dietrich 2003).
As pointed out, both ischemic insult and reperfusion results in delayed cell
death by disrupting the blood brain barrier allowing infiltration of peripheral
immune cells. The initial mechanisms of both injuries are different but converge
on the modulation of inflammation to amplify and exacerbate disease pathology.
Therefore animal models used for the development of stroke therapeutics should
aim to eliminate the over production of these proinflammatory mediators.

Animal Models of Stroke
An assortment of animal models to evaluate stroke related pathology has
been developed to assess new therapeutics. Importantly, basic research aims
specifically to translate beneficial effects of developing therapeutics from the
laboratory to clinical trials involving humans. Three basic animal models are
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currently utilized in stroke research: global ischemia, focal ischemia and
hemorrhagic injury (Richard Green, Odergren et al. 2003). In hemorrhagic animal
models, bleeding is induced in a specific brain region depending on the
hemorrhagic classification (intracerebral or subarachnoid). Global and focal
ischemias are the most commonly used animal models; therefore these topics
will be discussed further.

Global Ischemia
Global ischemia involves the blockage of one or more major arteries
resulting in significant CBF reduction in areas perfused by the occluded vessel,
thus mimicking ischemic injury (Traystman 2003). Global ischemia can be
performed by varying techniques including bilateral carotid occlusion, two vessel
occlusion plus hypotension, or a four vessel occlusion (Richard Green, Odergren
et al. 2003). Bilateral carotid occlusions are achieved using an incision to expose
both carotid arteries, the vessels are isolated and ligated most commonly using a
silk suture (Fujishima, Morotomi et al. 1979).
In the permanent occlusion model, the occlusion/ligation is permanent; in
the transient model, the method of occlusion is reversed following an allotted
time to restore blood flow. Use of the permanent model aims to investigate stroke
induced infarct, while the transient model is used to investigate both stroke
induced infarct and reperfusion injury.
Two vessel occlusion plus hypotension employs the same technique as
described in bilateral carotid occlusion, but hypertensive animals are used. This
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model intends to examine the cumulating effects of both high blood pressure and
ischemia. Four vessel models incorporate the bilateral carotid model, but also
added the occlusion of two vertebral arteries (Pulsinelli and Brierley 1979). This
procedure calls for the occlusion of all four major arteries that supply blood to the
brain. This method produces a significant decrease in CBF resulting in global
ischemia (Pulsinelli and Brierley 1979). Although the four vessel occlusion model
restricts all major vessels supplying the CNS, blood still reaches the brain
through the collateral and anterior spinal arteries in the para vertebral and
cervical muscles (Pulsinelli and Buchan 1988). Therefore a complete global
ischemia is not achieved in the models mentioned, although the four-vessel
model produces the most significant reduction in CBF. Myocardial infarctions are
the only method used to produce a complete global ischemia. Although effective
and easily replicated, global ischemia is not comparable to the human model of
stroke. Global ischemia is less relevant to the human stroke condition because
global ischemia is not a common feature of human stroke, but does have a place
in the study of cardiovascular incidents. In the human population, focal ischemia
is the major injury pattern observed (Traystman 2003).

Focal Ischemia
Focal ischemia entails the obstruction of a specific vessel, creating an
infarct in areas perfused by the vessel. This model is primarily achieved by
obstructing the middle cerebral artery; a procedure which reduces CBF mainly to
the striatum and cortex (Garcia, Liu et al. 1995; Kanemitsu, Nakagomi et al.
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2002). Middle cerebral artery occlusion (MCAO) is achieved by isolating both the
external and the common carotid, from which the MCA is obstructed either by the
introduction of a filament, suture or photothrombosis (Carmichael 2005). In the
filament model, a line is introduced at the base of the internal carotid artery and
advanced into the MCA. In the suture model, a silk thread is used to tie off the
internal carotid artery, thus restricting blood flow to areas perfused by the MCA.
On the other hand, the photothrombosis model involves the use of
photooxidation to develop a clot in the target vessel, providing the necessary
occlusion resulting in reduced CBF.
Following MCAO, cell death is rapid in the striatum and cortex, and the
expansion of the infarct via apoptotic cascades are time dependent (Garcia, Liu
et al. 1995; Carmichael 2005). Infarction areas are thus relative to MCAO
duration. MCAO induced striatum and cerebral cortex dysfunction produces
motor, autonomic and cognitive deficits (Carmichael 2005). These deficits are a
result of stroke led degeneration of areas integral to the execution of such
functions. In humans, occlusion of the middle cerebral artery is the most common
cause of an ischemic event, therefore occlusion of the MCA in animal models
serves to develop specific treatments that would benefit a large population of
patients (Traystman 2003). Like models of global ischemia, the MCAO model of
focal ischemia can be transient or permanent. In the transient model, the vessel
is obstructed for a period of time, followed by removal of the obstructive force,
where in the permanent model the obstruction is not removed. Ischemia plus
reperfusion is studied in the transient model, where only the ischemic damage is
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accessed in a permanent occlusion model (Richard Green, Odergren et al.
2003).
All models mentioned produce global or focal ischemia. These models
provide

reproducible

effects

tailored

towards the

research

of

specific

investigators. Each model provides benefits and drawbacks and is used
specifically for the length of time required for the ischemic damage as it
correlates to the region of the brain affected.

Moving Past the Neuron-Centric Perspective
A primarily neuron-centric approach has influenced the past decade of
stroke related research.

Specifically, this movement is primarily aimed at

neuronal preservation and stabilization following ischemic injury. This neuroncentric approach has led to an overwhelming proportion of research focused at
limiting ischemic damage to the gray matter; thus the current literature is
saturated with experimentations studying the effects of stroke on gray matter. As
a result, very little has been published investigating white matter pathology
although it plays a significant role in the debilitating disease that is stroke. The
white matter, like the gray matter, is significantly impacted by ischemic brain
injury. Cerebral white matter accounts for 50% total brain volume in humans,
oligodendrocyte (OL) are the major cell type of the white matter and are integral
in proper brain function (Miller, Alston et al. 1980). The significance of this region
has contributed to an emerging consensus highlighting the importance of OLs
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and the white matter in research aimed at limiting functional deficits resulting
from stroke induced pathology (Arai and Lo 2009).

White Matter
Overview
By volume, the white matter account for 50% total brain volume in humans
and is responsible for efficient synaptic transmission and proper cerebral
function. It is of no surprise that white matter damage can be more devastating
than comparable gray matter injury when similar size areas are affected by
stroke (Goldberg and Ransom 2003). Mature OLs of the cerebral white matter
myelinate the central nervous system (CNS). The myelin produced by OL,
ensheaths neuronal axons to facilitate fast and efficient synaptic transmission.

OL Development
OL progenitors arise in vivo from cells of the subventricular zone of the
lateral ventricles, differentiate, then migrate to regions of developing white and
grey matter until reaching the appropriate axons (Levison and Goldman 1993).
After reaching their target axons OLs exit the cell cycle, become non-migratory
and differentiate into myelin producing OLs. During maturation, OLs begin to
down regulate precursor OL proteins including platelet derived growth factor
alpha receptor (PDGF-AA) and NG2 chondroitin sulfate proteoglycan and induce
the expression of proteins, such as myelin basic protein (MBP) (McTigue and
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Tripathi 2008). Upon beginning the expression of myelin proteins, OLs have fully
developed into the mature phenotype.
Myelination occurs in the following four stages: the recognition and
adhesion of an OL to an axon, synthesis and transport of myelin to axon,
wrapping of myelin around axon, and finally compaction of myelin sheath. During
the myelination process, only axons with a diameter greater than 0.2µm are
ensheathed.

Unlike Schwann cells of the peripheral nervous system that

myelinate axons at a 1:1 ratio, OLs have the ability to myelinate 40-60 different
axons simultaneously.

During the active phase of myelination, each OL

produces an estimated 5.50 X 103 µm2 of myelin membrane surface area per
day, a process requiring a large expenditure of energy (Pfeiffer, Warrington et al.
1993; Taveggia, Zanazzi et al. 2005; Simons and Trajkovic 2006).
Myelin sheaths are formed by the coiled wrapping of glial plasma
membrane extensions around axons followed by the extrusion of cytoplasm and
the compaction of the stack membrane bilayers.

Myelin sheaths are rich in

glycosphingolipids and cholesterol to provide insulation of axons to maximize
conduction velocity (Simons and Trajkovic 2006). By weight, myelin is composed
of 30% protein and 70% lipids; the two major protein classes are MBP and
proteolipid proteins (PLP). Minor proteins such as CNPases, myelin associated
glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG) are also
present (Morell, Greenfield et al. 1972; Larocca and Rodriguez-Gabin 2002). In
addition, proteins are synthesized in different regions based on function. MBP
and myelin oligodendrocyte associated basic proteins (MOABP) are synthesized
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close to the site of myelin assembly (Colman, Kreibich et al. 1982; Barbarese,
Koppel et al. 1995; Gould, Freund et al. 1999). PLP and MAG are synthesized in
the endoplasmic reticulum, then transported by vesicles to the Golgi. From the
Golgi these proteins are transported via COPI and COPII to the forming myelin
sheath. Cooperatively, both the minor and major proteins of myelin function
together to maintain the myelin sheath, and the absence of one could be
destructive to the sheath stability (Townsend and Benjamins 1983; Bizzozero,
Soto et al. 1984).
In addition to myelination, OLs serve an important role supporting the
survival and function of neighboring neurons.

OLs regulate axonal size, ion

channel clustering such as sodium (Na+) and potassium (K+) and also produce
trophic factors including insulin like growth factor 1 (IGF-I), nerve growth factor
(NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3) and
neurotrophin 4/5 (NT-4/5) (Du and Dreyfus 2002).

Additionally, failures and

abnormalities in myelination are implicated in disruptions of normal impulse
conduction and interference with neurological function and can potentially lead to
neuronal loss (Noble 2005 ). The importance of myelination is evident not only in
demyelination diseases such as multiple sclerosis, but also in mice lacking the
major proteolipids of myelin. These animals tend to experience axonal swelling
and degeneration (Du and Dreyfus 2002).
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Stroke and Oligodendrocytes
CNS myelination is the primary function of white matter OLs. As a result,
the primary consequence of OL death is axonal demyelination.

Axonal

demyelination leads to delays or complete blockage of axonal conduction, which
results in impaired neuronal signaling and cell death. OLs are also responsible
for normal axonal transport as well as microtubule levels.

Lack of myelin

contributes to elevated microtubule numbers but a sharp decrease in microtubule
stability (McTigue and Tripathi 2008). Additionally, OLs like neurons and
astrocytes are known to have very high metabolic rates. These high metabolic
demands render OLs inherently susceptible to ischemia. Naturally, of the
different types of glia, OLs were found to be the most prone to hypoxic and/or
glucose deprived conditions (Lyons and Kettenmann 1998). OL injury is
important as it relates to the treatment of stroke. Therefore it is important to
understand stroke induced OL dysfunction that treatments can be tailored to
maintenance of cerebral white matter following injury.

Oxidative Stress
Oxidative stress is one of the most frequent causes of stroke induced OL
dysfunction. Cellular stress is increased during anaerobic respiration after
ischemia, particularly during reperfusion (Dewar, Underhill et al. 2003). Of the
compounds produced in OGD environments, ROS and RNS are the most
detrimental to cellular homeostasis. ROS are natural by products of oxygen
metabolism and are metabolized into benign compounds under normal
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physiological condition. Yet, under biological stress, ROS are generated to toxic
levels causing cellular dysfunction (Allen and Bayraktutan 2009). The brain is
especially prone to ROS induced damage, the abundance of peroxidizable lipids
and natively high oxygen consumption are the main culprit. In the in vitro stroke
model OGD, aerobic respiration is disrupted resulting in the accumulation of
respiratory chain intermediates allowing electron leak to generate ROS
(Abramov, Scorziello et al. 2007). Superoxide is the primary ROS from which
other more reactive ROS are generated. Superoxide generates hydrogen
peroxides, which generates hydroxyl radicals. RNS are also generated from the
interaction of nitrogen and superoxide. These intermediates include nitric oxide,
peroxynitrous acid that produces hydroxyl radical. The accumulation of these
radicals depends on the oxidizable substrate, availability of oxygen and
antioxidant enzymes (Allen and Bayraktutan 2009).
OLs are susceptible to oxidative stress due to the large amount of energy
necessary to synthesize and maintain myelin. Myelination is an energy
dependent process and requires large amounts of ATP and oxygen consumption.
As described above, OGD leads to overproduction of superoxide leading to
hydrogen peroxide and ROS byproducts which if not metabolized cause OL
deoxyribonucleic acid (DNA) damage, lipid per-oxidation and apoptosis. OL
susceptibility to oxidative stress is also a result of myelin synthetic enzymes that
requires co-factors such as iron. Of cerebral cell types, OLs possess the largest
intracellular iron stores. Iron is highly reactive, when oxidized it reacts vigorously
resulting in to free radical formation (McTigue and Tripathi 2008). For example,
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hydroxyl radical is generated from hydrogen peroxide by ferrous iron that has
been reduced by superoxide (Allen and Bayraktutan 2009). Following ischemic
injury, free radical formation as a result of iron oxidation is rapidly increased
causing lipid peroxidation. In conjunction with elevated iron levels, OLs possess
low anti-oxidants stores. Glutathione is one such anti-oxidant (McTigue and
Tripathi 2008). Relative levels of antioxidants are important to maintain the
balance of ROS without accumulating enough for a toxic effect. OLs low antioxidant stores encourage rapid accumulation of ROS leading to accelerated
cellular dysfunction.
Additionally, sphingolipids are a major component of myelin synthesis and
play a damaging role in OL injury. Sphingolipids contain ceramide cores that
coalesce to form domains enriched in death receptors following injury. These
death receptors include CD95, tumor necrosis factor receptor. In addition, the
clustering of ceramide cores increases the sensitivity of OLs to death receptor
signaling. But this represents only one way in which ceramides contribute to OL
injury. Ceramides can also be released intracellularly by enzymatic cleavage of
membrane sphingolipids by sphingomyelinase (SMase).

This enzyme is

normally inactive but is activated during CNS injury such as stroke (McTigue and
Tripathi 2008).
Excitotoxicity, in which α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)/Kainate receptors are over stimulated, also plays a role in ischemic
OL death. These receptors are stimulated as a result of glutamate, excessive
stimulation of these receptors leads to elevated intracellular calcium. Elevated
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intracellular calcium initiates cascades activating enzymes that degrade
cytoskeleton proteins causing mitochondrial disruption leading to ROS production
and cytochrome c release (McDonald, Althomsons et al. 1998). Following an
ischemic event, as stated above, a variety of cytokines and chemokines are
released in the cellular space by a variety of cells. The cytokines interleukin 1
beta (IL-1β), interleukin 2 (IL-2), interferon gamma (IFNγ) and tumor necrosis
factor alpha (TNF-α) have all been shown to promote OL death directly or
indirectly (McTigue and Tripathi 2008). TNF-α and IFNγ signaling induce free
radical production, which results in OLs cell death through oxidative stress as
previously described. TNF-α can also directly kill OLs by binding to the p55 TNF
receptor which initiates DNA degradation and caspase independent apoptosis
(McTigue and Tripathi 2008).
With the mechanisms of white matter injury outlined above, it is important
to tailor treatment specific to arrest these processes. Few in vitro treatments are
efficacious in vivo, and a minute number of these successful treatments are
assessed in clinical trials. Below, treatments that have attained some promise in
clinical trials will be discussed.

Clinical Trials
Treatment following an ischemic event does not aim to affect the
immediate necrosis at the core of the infarct, but to prevent the expansion of the
infarct core. Chemicals identified as potential stroke treatment are first examined
in a laboratory setting beginning with in vitro stroke models. OGD is the most
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commonly used in vitro stroke model, where cellular media is devoid of glucose
and cells are exposed to an oxygen deficient environment for an extended period
of time. If in vitro trials are successful, in vivo studies are performed using animal
models, after which, viable therapeutics are scheduled for human clinical trials
following FDA approval. Over 150 clinical trials investigating therapeutic agents
targeting ischemic injury have been performed. These therapeutics are classified
as nonpharmacologic, antithrombotic and neuroprotective agents, all but one
resulted in failure (Kidwell, Liebeskind et al. 2001). A successful drug is defined
as a drug approved by the FDA for treatment. So far the only such existing drug
is the thrombolytic agent t-PA. With limited patients qualifying for treatment with tPA, basic scientists like clinicians have recognized the urgent need for new
therapeutics to combat the ever-growing disease that is stroke. As a result over
recent decades, not only have clinical trials increased, but the sample size
attributed to each trial has also increased (Kidwell, Liebeskind et al. 2001).

Neuroprotective Agents
Neuroprotective trials examined drugs that promote membrane repair, free
radical scavengers, antiedema, metabolic activations, modulators of calcium
influx, and modulators of excitatory amino acids (Kidwell, Liebeskind et al. 2001).
Many of these drugs were successful in vitro and showed promise in several in
vivo animal models. Yet, the cellular protection and behavioral recovery observed
in vivo has not transferred to human clinical trials. The lack of success in human
trials could be attributed to the controlled environment in which animal studies
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are performed. In animals, specific stroke models elicit damage in specific areas
of the brain. Additionally, the success of a drug is usually based on the action of
treatment in specific brain areas; therefore an overall protective view including
behavioral recovery is often overlooked. Also the side effects of these drugs are
usually not completely understood or evaluated (Richard Green, Odergren et al.
2003). An example of such a neuroprotective agent is the use of nimodipine, a
calcium antagonist. Nimodipine specifically blocks the influx of calcium following
ischemia, thus arresting excessive cellular stimulation and cell death attributed to
excitotoxicity (Steen, Gisvold et al. 1985). Nimodipine was successful in vitro and
in animal models at reducing cell death and infarct volume respectively, but
outcomes following ischemic injury were not improved in human trials (Steen,
Gisvold et al. 1985; Horn, de Haan et al. 2001). In addition, nimodipine had an
unintended side effect of lowering patient’s blood pressure and have been shown
to worsen outcome following stroke. This side effect was identified only after the
drug was evaluated in human trials (Ahmed, Nasman et al. 2000; Horn, de Haan
et al. 2001; Richard Green, Odergren et al. 2003).

Addressing Failure
Nimodipine, like other neuroprotective and nonpharmacologic drugs,
experienced success in animal studies but failure in human clinical trials. The
high failure rate of treatment for ischemic injury could be attributed to the
monotherapy performed in clinical trials and the neuron-centric view. Stroke is a
multicellular disease meaning the entire CNS is affected following an ischemic
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insult. Neurons and glial cells are adversely affected by ischemia, and responds
in varying ways. Thus, diverse cellular populations are affected in an ischemic
attack. Therefore different pathways and substrates contribute to the expansion
of the infarct and the final outcome of the disease. A narrow focus on the gray
matter to combat stroke pathology is naive. A broad view addressing both gray
and white matter injury as a result of stroke is necessary to the development of
new therapies.

Antithrombotics
Antithrombotic trials evaluate agents that increase blood flow, many of
which are anticoagulants, fibrinolytic and antiplatelet compounds (Kidwell,
Liebeskind et al. 2001). This area of study, thus far, has been the most
successful, with the advent of t-PA, the only FDA approved treatment for
ischemic injury.

Tissue Plasminogen Activator
t-PA was approved by the U.S Food and Drug Administration (FDA) in
1996, and is still the only thrombolytic drug approved as treatment for an acute
ischemic injury (Pan, Yu et al. 2008). t-PA is a serine protease enzyme that
converts plasminogen to plasmin. Thrombotic clots are formed from fibrin and
platelets by the body to inhibit blood loss, when these clots enter the circulatory
system a thrombosis can result. t-PA works by cleaving plasminogen into
plasmin, this cleavage activates plasmin which cleaves fibrin (Slaets, Dumont et
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al. 2008). Thus, t-PA alike other thrombolytics works by dissolving clots, and
therefore restores blood flow to ischemic areas. t-PA treatment within 3 hrs of
stroke onset significantly reduces the effects of stroke (Hacke, Donnan et al.
2004). This cited study also reported that benefits were also seen 4 hrs following
stroke but negligible to no benefit was observed when given 6 hrs post stroke.
Although beneficial, usage of this treatment increased the patient’s risk of a
possible hemorrhagic event (Wardlaw, Warlow et al. 1997). The American Heart
Association reports that only 3-5% of stroke patients employ this treatment,
based on the time qualifications and the specificity of treatment only to ischemic
injury. To qualify for t-PA treatment, a patient must first recognize the onset of the
stroke, get to the hospital, have a CT scan performed to specify that the stroke is
ischemic in nature and then receive treatment if all required criterions are met.
The most stringent of these qualifications is the 3 hrs time window within which a
patient must be evaluated and deemed eligible for treatment (Marler and
Goldstein 2003).

Stem Cells
Unlike previously discussed therapeutics, stem cell therapy first aimed to
reduce the progression of stroke pathology by replacing neurons that have
succumbed to the ischemic insult, and promote neurogenesis while extending the
therapeutic time window for treating strokes. Unlike other cell replacement
therapies, stem cell therapies initially aimed to generate and replace not just one
specific cell type, but a large and varying population of cells. Thus far various
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sources of stem cells have been tested to improve function following
transplantation in animals subjected to stroke. Promising results were shown
using a mouse neuroepithelial stem cell line, human NTera-3 cell line and human
bone marrow/mesenchymal stem cells (Fujishima, Morotomi et al. 1979).
Ischemia potentiates the secretion of neurotrophins and bioactive factors by
mesenchymal stem cells (MSC) (Oh, Fujio et al. 1998). In animal studies, MSCs
released bioactive factors in the ischemic boundary, reducing cellular apoptosis
and induced cellular proliferation. Regeneration was observed, where newly
formed cells expressed proteins identifiable to progenitor like neuron and
astrocytes (Chen, Li et al. 2003). Although cellular recovery has been identified in
vivo following stem cell treatment, evidence shows very little of the transplanted
cells survive and migrate to the brain (Fujishima, Morotomi et al. 1979). Thus, it
is now evident that stem cells do not replace dysfunctional cells in the ischemic
boundary, but promote repair and neurogenesis.
Stem cell transplantation in human trials has shown some success; this
included the use of human neuronal cells derived from a human teratocarcinoma
line and fetal porcine cells.

The use of human teratocarcinoma showed

improvements in patients tested on the European stroke scale, but in phase II
trials, no improvement in outcome as tested by the European Scale after six
months was reported although improvements were observed in the Action Arm
Research Test and the Everyday Memory Test (Kondziolka, Wechsler et al.
2000; Bang, Lee et al. 2005). A small study using fetal porcine cells was quickly
terminated by the FDA after patients reported seizures and increased
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neurological deficits weeks following transplantation (Marler and Goldstein 2003).
The most promising of the stem cell study involved the use of autologous marrow
stem cells (aMSCs). In experiments where aMSCs were administered
intravenously 4-5 or 7-9 weeks following initial onset of stroke in humans,
behavioral recovery was reported using two different exams. When compared
against control, aMSC treated patients did not show a reduction in infarct volume
but improvements were observed in both the Barthel index and modified Rankin
scale (Bang, Lee et al. 2005). Both Barthel and modified Rankin scales are used
to measure performance in basic activities of daily living, assessing the likelihood
of being able to live at home independently following discharge from the hospice
(Mahoney and Barthel 1965; van Swieten, Koudstaal et al. 1988). Distinctly, the
modified Rankin scale is the most widely used clinical outcome measure for
stroke.

Human Umbilical Cord Blood Cell
Origin
Human umbilical cord blood (HUCB) cells represent a cellular population
taken from the placental umbilical cord of newborns. HUCB cells are easily
retrieved and available unlike cells such as bone marrow that requires the use of
painfully extraction techniques to access the cells. Furthermore, because of the
characteristic immaturity of these cells, there is a lower incidence of graft versus
host disease following cell transplantation compared to other cell based therapies
(Lewis 2002). An additional benefit is the ability of HUCB cells to be
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cryopreserved for later use, HUCB cells are effective three years following initial
cryopreservation (Goodwin, Grunzinger et al. 2003). The mononuclear fractions
of HUCB cells are typically used in therapy. This mononuclear fraction is
composed of 77% lymphocytes, 23% monocytes and less than 1% CD34
hematopoietic stem cells. The lymphocyte population contains approximately
47% T lymphocytes. (Pranke, Failace et al. 2001).

Cellular Protection
The use of HUCB cells as a therapeutic treatment for stroke is a growing
field of study, especially with the initial success of laboratory trials. OLs coincubated with HUCB cells and exposed to OGD showed reduced activated
caspase 3 immunoreactivity compared to untreated cells. In vivo, white matter
bundles were preserved in animals treated with HUCB cells compared to MCAO
groups not treated with HUCB cells (Hall, Guyer et al. 2009). Moreover, following
MCAO, HUCB cells migrate to the site of injury to reduce infarct volume and
improve behavioral recovery (Vendrame, Cassady et al. 2004; Newman, Willing
et al. 2005; Hall, Guyer et al. 2009). The cytokine monocyte chemoattractant
protein-1 (MCP-1) and macrophage inflammatory protein (MIP-1α) are
responsible for these chemotactic effects promoting HUCB cell migration to the
ischemic area ipsilateral to the infarct (Jiang, Newman et al. 2008). In the
assessment of behavioral recovery, intravenous administration of HUCB cells 48
hrs post MCAO significantly improved motor recovery as measured by the step
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test and accelerated rotorod test one-month post stroke (Newcomb, Ajmo et al.
2006).

Anti-inflammatory Effects
HUCB cells not only exert effects on the brain of an ischemic animal, but
also modulate the immune system. Administration of HUCB cells reduced stroke
induce pro inflammatory response by blocking the infiltration of peripheral
immune cells such as leukocytes (Vendrame, Gemma et al. 2005). This
reduction of microglia, macrophage and B cells recruitment to the infarct reduced
the production of pro inflammatory mediators TNF-α, IL-1β and IL2 expression
following stroke (Vendrame, Gemma et al. 2005). HUCB cell modulation of pro
inflammatory effectors was also evident in the spleen. Post MCAO, About 1% of
HUCB cells were found to migrate to the spleen following intravenous treatment
(Chen, Sanberg et al. 2001). While, splenectomy before MCAO reduced the
activation of both peripheral and resident CNS immune cells in the brain. The
reduction of immune cell activation arrested stroke pathology, where reduction in
flouro jade positive cells was evident in the infarct area (Ajmo, Vernon et al.
2008). These experiments identified pleio-effects of HUCB cells; HUCB cells act
at the point of the CNS but also modulate and suppress the immune response
following an ischemic insult.
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HUCB Cells Secrete Soluble Factors
The reported protective effects following HUCB cell systemic injection post
ischemia is attributed to the soluble factors secreted by these cells. Upon
stimulation of HUCB cells by epidermal growth factor/ fibroblast growth factor-2
(EGF)/ (FGF-2) or nerve growth factor/retinoic acid (NGF/RA), a vast number of
soluble factors were secreted by HUCB cells. These factors included interleukins,
growth factors, chemokines and metalloproteinase inhibitors. Many of the
secreted factors are known for their pro-survival effects, including interleukin 6
(IL-6), interleukin 8 (IL-8), and interleukin 10 (IL-10) (Neuhoff, Moers et al. 2007).
Other factors are known for proliferative effects, such as vascular endothelial
growth factor (VEGF), BDNF, platelet derived growth factor B (PDGF-B),
leukemia inhibitory factor (LIF), and granulocyte colony stimulating factor (GCSF)
among others and are known to activate survival pathways including
phosphoinositide 3 kinase (PI3)/Akt (Kulik, Klippel et al. 1997; Jin, Mao et al.
2000; Newman, Willing et al. 2006; Neuhoff, Moers et al. 2007). The
aforementioned findings established HUCB cell treatment as a possible
therapeutic candidate for delayed treatment of ischemic injury. Yet, there are
strong concerns with regards to the use of HUCB cells; these concerns include
the ethical use of cell based therapy. Therefore, it is of utmost importance to
investigate and find soluble factors that emulate the effects of HUCB cells; LIF
represents one such soluble factor.
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Leukemia Inhibitory Factor
Here we will discuss LIF, a pleiotropic cytokine secreted by HUCB cells.
LIF is a 180 amino acid single 4-α-helix glycoprotein (Kurek 2000; Metcalf 2003)
that works through the LIF cell surface receptor complex which includes the LIF
receptor β (LIFR) and the gp130 receptor chain (Kurek 2000). Cells throughout
the body express LIFR. While LIF specifically interacts with the LIFR, it binds at a
low affinity, but this affinity is increased once LIF is bound to the gp130 (Gearing,
VandenBos et al. 1992; Kurek 2000). Following LIF binding, LIFR and gp130
dimerizes and activates the gp130 intracellular signaling cascade. The activation
of gp130 results in the activation of the Janus kinase signal transducer and
activator for transcription (JAK/STAT) pathway, Ras mitogen activated protein
(MAPK) and the phosphatidylinositol 3 kinase (PI3/Akt) (Stahl, Boulton et al.
1994; Stahl, Farruggella et al. 1995; Oh, Fujio et al. 1998).
LIF mRNA has been found in both peripheral nervous system (PNS) and
the CNS. LIF is expressed by Schwann cells, neurons and glial cells including
astrocytes and microglia (Lemke, Gadient et al. 1996; Banner, Moayeri et al.
1997; Cheng and Patterson 1997; Dowsing, Morrison et al. 1999). Thus, LIF has
pleiotropic effects ranging from the induction of cellular proliferation to the
maintenance of cultured murine embryonic stem cell totipotentiality (Williams,
Hilton et al. 1988). Specifically in the CNS, LIF was shown to have both
proliferative and protective effects on glial cells.

LIF stimulated glial fibrillary

acidic protein (GFAP) expression in astrocytic progenitors, whereas in OL
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progenitor cultures, LIF enhanced myelin basic protein expression, survival, and
maturation (Mayer, Bhakoo et al. 1994; Nakagaito, Yoshida et al. 1995)
In disease states, LIF have been shown to attenuate the progression of
pathological disorders. LIF enhanced neuronal survival when placed at the site
of axotomized sensory and motor neurons (Oh, Fujio et al. 1998). LIF treatment
rescued OLs and reduced demyelination following spinal cord injury through
STAT 3 and PI3/Akt survival pathway activation (Metcalf and Gearing 1989;
Azari, Profyris et al. 2006). Furthermore, LIF administration attenuated
demyelination and OL loss in experimental autoimmune encephalomyelitis
(EAE), the mouse model of multiple sclerosis, where the addition of anti-LIF
antibody exacerbated EAE disease pathology (Metcalf and Gearing 1989;
Metcalf and Gearing 1989; Butzkueven, Zhang et al. 2002). LIF rescued mature
cultured OLs from interferon γ and tumor necrosis factor α induced cell death,
through the activation of both JAK/STAT and PI3/Akt pathway (Slaets, Dumont et
al. 2008).
The release of pro-inflammatory cytokines following ischemic injury leads
to the expansion of the umbra, via activation of cellular cascades resulting in
macrophage activation and cell death. Therefore the discovery that LIF inhibits
the production of pro-inflammatory mediators including TNFα and ROS by
macrophages is relevant to the development of therapies against the progression
of stroke pathology (Hendriks, Slaets et al. 2008). Furthermore, endogenous LIF
peaked between 90 min and 24 hrs following MCAO in the peri ischemia area in
rats, a result that maybe explained as an intrinsic attempt by the brain to combat
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the ischemic insult (Suzuki, Tanaka et al. 2000; Slevin, Krupinski et al. 2008). LIF
is selectively blood brain barrier permeable, thus, under pathological conditions
such as spinal cord injury, there is an up regulation of LIF transport across the
blood brain barrier and into the brain (Mayer, Bhakoo et al. 1994). This was
shown when animals were subjected to lipopolysaccharide (LPS) treatment and
an up regulation of LIF transport system at the blood brain barrier was identified
(Pan, Yu et al. 2008). In a subsequent study the site directed treatment of LIF to
the cerebral cortex adjacent to the necrotic area following MCAO significantly
reduced infarct volume; this was more so a direct result of JAK stat activation
and to a lesser extent PI3/Akt activation (Suzuki, Yamashita et al. 2005).
The promising effects of LIF obtained both in cell culture and animal
model of different disease pathologies led to the development of a
pharmacological recombinant LIF. The pharmacological form of LIF was
developed to treat chemotherapy induced neuropathy. Phase 1 trials began in
1997 and a phase two trial is currently underway (Kurek 2000). Because of its
pleiotropic activity, caution is placed on the usage of LIF as a treatment. In
experiments where LIF was over expressed, animals showed weight loss,
overgrowth of medullary bone tissue in long bones, calcification of the liver heart
and skeletal muscle, thymus atrophy and the depletion of spermatogonia from
males seminiferous tubules of the testes (Metcalf and Gearing 1989; Metcalf and
Gearing 1989). On the other hand, the deletion of LIF results in an array of
abnormalities including abnormal development of the hippocampus, olfactory
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receptor neurons and the inability of females to become pregnant (Escary,
Perreau et al. 1993; Bugga, Gadient et al. 1998; Moon, Yoo et al. 2002).

AKT Survival Pathway
HUCB cells secrete growth factors, chemokines, matrix metalloproteinase
inhibitors and interleukins (Newman, Willing et al. 2006; Neuhoff, Moers et al.
2007). Of these soluble factors, many including IGF1, VEGF and LIF are known
to promote cell survival via Akt phosphorylation/activation (Kulik, Klippel et al.
1997; Jin, Mao et al. 2000; Neuhoff, Moers et al. 2007). These results implicate
the serine/threonine kinase Akt as a target of HUCB cell therapy. Upon
phosphorylation, Akt is an integral part of the cellular machinery involved in
survival. Phosphorylated Akt promotes survival by inhibiting the activation of
apoptotic substrates while stabilizing substrates involved in survival pathways
(Kennedy, Wagner et al. 1997). Activated Akt phosphorylates Bcl-2-associated
death promoter (BAD), pro caspase 9, Forkhead, and nuclear factor kappa B
(NFκb) (Datta, Brunet et al. 1999; Hanada, Feng et al. 2004; Zhao, Sapolsky et
al. 2006).
When unphosphorylated, substrates such as BAD targets Bcl-2 in the
mitochondria, causing cytochrome c release leading to caspase 9 cleavage
(Datta, Brunet et al. 1999; Zhao, Sapolsky et al. 2006). Caspase 9 is an initiator
caspase which proteolytically cleaves execution pro caspase 3 and caspase 7
(Cryns and Yuan 1998; Datta, Brunet et al. 1999). Caspase 3 plays a principal
role in the early apoptotic cascade leading to the cleavage of downstream

30

substrates such as poly (ADP-ribose) polymerase (PARP) (Nicholson, Ali et al.
1995; Le Rhun, Kirkland et al. 1998). PARP cleavage and NAD+ depletion as a
result of oxidative stress and DNA damage, leads to apoptosis inducing factor
(AIF) translocation to the cytoplasm from the mitochondria. AIF then migrates to
the nucleus where it induces chromatin lysis and cell death (Yu, Andrabi et al.
2006).

Thus,

aforementioned

phosphorylated
cell

death

Akt

promotes

cascades

and

survival
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by

blocking

the
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complexes through kinase activity (Kennedy, Wagner et al. 1997; Zhao, Sapolsky
et al. 2006).

Antioxidant Expression in the Brain
Delaying apoptotic cascades are necessary for inhibiting the progression
of stroke pathology, but combating the production of ROS and RNS also plays a
vital role. OL susceptibility to oxidative stress highlights an area that could be
exploited and prove beneficial to cellular homeostasis in the infarct boundary.
Thus, the identification and regulation of specific antioxidants in the cerebral
white matter post stroke could be a therapy defining focus. Two such
antioxidants are Mt3 and Prdx4. HUCB cells modulate both antioxidants
expression in the cerebral white matter OL (Rowe, Leonardo et al. 2010).

MT3
Metallothionein 3 (Mt3) is a small 68 amino acid protein that is extensively
involved in the storage and transport of metals such as copper. Mt3 is primarily
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expressed in the CNS and maintains cellular homeostasis via detoxification of
heavy metals such as mercury, and has also been shown to have antioxidant
functions against ROS and RNS (Hidalgo, Aschner et al. 2001). In disease
conditions, Mt3 is increased following stab wound in the cortex three days post
injury and expression is returned to basal levels three weeks following
experiment (Hozumi, Inuzuka et al. 1995; Hozumi, Inuzuka et al. 1996; Acarin,
Gonzalez et al. 1999). Using the stab wound model, Mt3 was shown to promoted
tissue repair following injury (Hozumi, Uchida et al. 2006). In disease states such
as Alzheimer’s (AD), Mt3 protein expression is significantly decreased. MT3 has
been postulated to play a role in the accumulation of amyloid beta plaques due to
the deregulation of zinc as a result of decreased Mt3 expression. Specifically,
zinc is an active component of plaque formation, thus the accumulation of zinc in
the absence of Mt3 is believed to exacerbate AD pathology (Uchida, Takio et al.
1991). A reduction in Mt3 was also observed post stroke. Following MCAO, Mt3
is gradual reduced until day 7, after which Mt3 gradually increased to basal levels
by day 28 (Inuzuka, Hozumi et al. 1996). Therefore the maintenance or
upregulation of Mt3 in affected tissue could play an active role in the attenuation
of disease progression.
HUCB cell treatment 48 hrs post MCAO increased Mt3 protein expression
and reduced apoptosis in the cerebral white matter (Rowe, Leonardo et al. 2010).
This protection points to Mt3 dual roles, activation of Akt survival pathway and
antioxidant function. Mt3 binds to TrkA receptor tyrosine kinases to activate the
PI3K/Akt signaling pathway reducing H2O2 and doxorubicin (Dox) induced
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caspase activation and cell death (Kim, Hwang et al. 2009). An additional study
showed that Mt3 protects against oxidative stress via Akt activation and
upregulating heme oxygenase 1, resulting in decreased ROS generation,
caspase 3 activation and neuronal cell death (Hwang, Kim et al. 2008). In these
experiments assessing Mt3 induced Akt activation, the use of Akt inhibitors
completely abolished the protection conferred by Mt3 treatment (Hwang, Kim et
al. 2008; Kim, Hwang et al. 2009). Mt3 attenuated glutamate neurotoxicity by
quenching nitric oxide (NO) elicited by glutamate (Montoliu, Monfort et al. 2000).
Furthermore, Mt3 knockout animals showed increased susceptibility to kainic
acid whereas over expression of Mt3 reduced this susceptibility to kainic acid and
increased resistance to kainic acid (Erickson, Hollopeter et al. 1997). Mt3 has
also proven to rescue neurons by activating NFκb via the phosphorylation of IκBα
leading to IκBα degradation (Kim, Hwang et al. 2009). Thus, the regulation of Mt3
contributes to cellular detoxification and the activation of survival pathways
leading to cell survival in various disease states.

Prdx4
Peroxiredoxin (Prdx)4 is an additional antioxidant upregulated following
HUCB cell treatment in the external capsule of rats subjected to MCAO (Rowe,
Leonardo et al. 2010). Prdxs are biological antioxidants. This family of antioxidant
enzymes function through peroxidase activity reducing hydrogen peroxide,
peroxynitrite and other organic hydroperoxides (Hofmann, Hecht et al. 2002). Six
different Prdx have been classified to date; all have a common catalytic
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mechanism of being unfolded, fully folded or a conserved conformation. Prdx4
mechanism involves the oxidation of a cysteine residue by the peroxide substrate
causing a conformational change allowing the formation of a disulfide with the
cysteine residue (Hall, Karplus et al. 2009). This action catalytically convert
substrates such as hydrogen peroxide to water. This activity detoxifies the
cellular environment, and the active enzyme is regenerated following reduction of
the disulfides (Zito, Melo et al. ; Hall, Karplus et al. 2009). This cycle is referred to
as the thiol/sulfenic acid redox cycle (Tanaka, Hijioka et al. 2004). There have
been at least six identified peroxiredoxins but only Prdx4 has been shown to
regulate thromboxane A2 receptor that regulates oxidative stress (Giguere,
Turcotte et al. 2007). Thromboxane A2 receptor is known to be upregulated by
oxidative stress and has been shown to contribute to cellular injury upon
activation during oxidative stress (Valentin, Field et al. 2004). Prdx4 also
undergoes structural changes in response to oxidation; this activity is thought to
prevent free radical induced aggregation of proteins (Jang, Lee et al. 2004; Kang,
Rhee et al. 2005). Oxidative stress leads to protein unfolding in the cytoplasm;
the chaperone activity of Prdx4 prevents the aggregation of these proteins,
where protein aggregation is known to facilitate disease pathology. In mouse, the
over expression of Prdx4 prevented p53 or epidermal growth factor induced
mitochondrial ROS production (Wong, Chun et al. 2000). The inhibition of ROS
production by Prdx4 over expression highlights the importance of this protein in
the prevention of ROS induced cellular dysfunction. The literature has shown the
importance of antioxidants in the brain following ischemic injury. Among these,
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Prdx4 could play a vital role in the preservation of cells and reduction in stroke
induced morbidity and potential mortality.

HUCB Cells Therapy to Protect the White Matter OL
Presently, our laboratory is investigating HUCB cells as a potential
treatment for stroke. In a report published by Hall. et al, our laboratory has
demonstrated the protective nature of HUCB cell treatment on OLs subjected to
OGD. Yet, the mechanisms by which HUCB cell rescue OLs remains to be
established. Here we will examine how these cells protect OLs and evaluate the
mechanism of action. These experiments are discussed herein.
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Abstract
Oligodendrocytes (OLs), the predominant cell type found in cerebral white
matter, are essential for structural integrity and proper neural signaling. Very
little is known concerning stroke-induced OL dysfunction. Our laboratory has
shown that infusion of human umbilical cord blood (HUCB) cells protects striatal
white matter tracts in vivo and directly protects mature primary OL cultures from
oxygen glucose deprivation (OGD). Microarray studies of RNA prepared from
OL cultures subjected to OGD and treated with HUCB cells showed an increase
in the expression of 33 genes associated with OL proliferation, survival, and
repair functions, such as myelination. The microarray results were verified using
quantitative RT-PCR for the following eight genes: U2AF homology motif kinase
1 (Uhmk1), insulin induce gene 1 (Insig1), metallothionein ( Mt3), tetraspanin 2
(Tspan2),

peroxiredoxin

oligodendrocyte

4

(Prdx4),

glycoprotein

stathmin-like

(MOG),

and

2

(Stmn2),

versican

myelin
(Vcan).

Immunohistochemistry showed that MOG, Prdx4, Uhmk1, Insig1 and Mt3 protein
expression were upregluated in the ipsilateral white matter tracts of rats infused
with HUCB cells 48 hrs after middle cerebral artery occlusion (MCAO).
Furthermore, promoter region analysis of these genes revealed common
transcription factor binding sites, providing insight into the shared signal
transduction pathways activated by HUCB cells to enhance transcription of these
genes. These results show expression of genes induced by HUCB cell therapy
that could confer oligoprotection from ischemia.
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myelin basic protein; GFAP, glial fibrillary acidic protein; RIP, Receptor
interacting protein; EVI1, ecotropic viral integration site 1; MZF1, myeloid zinc
finger protein; GATA1, GATA-binding factor 1; NK6.1, NK6 homeobox 1; PAX6,
pax-6 paired domain binding site; Sox-5, SRY (sex determining region Y)-box 5;
SRF, serum response factor; ROS, reactive oxygen species; VEGF, vascular
endothelial growth factor; IL-6, interleukin 6; H-I, hypoxic ischemia; AU,
absorbance units.
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Introduction
Stroke is the third leading cause of death in the United States, with
ischemic strokes accounting for 83% of all strokes (Lloyd-Jones, Adams et al.
2009). Ischemic brain injury affects both white and gray matter. Although white
matter integrity is essential to proper neuronal communication, much of current
research is focused exclusively on neuronal damage.

Accounting for 50% of

brain volume in humans, white matter and the oligodendroglia that myelinate
these areas play an integral role in proper brain function (Miller, Alston et al.
1980). The myelin produced by OLs not only supports axonal structural integrity,
but is also essential in impulse integration (Baumann and Pham-Dinh 2001).
Thus, white matter protection is necessary to dampen stroke-induced injury and
its progressive pathology (Arai and Lo 2009).
In addition to myelination, OLs support the survival and function of
neurons by regulating axonal size and ion channel clustering. OLs also secrete
trophic factors such as BDNF, NGF, GDNF and IGF-1, all of which aid in cell
survival and maintenance (Baron-Van Evercooren, Olichon-Berthe et al. 1991;
Kaplan, Meyer-Franke et al. 1997; Wilkins, Majed et al. 2003; Noble 2005 ). Of
the different types of glia, OLs are the most vulnerable to hypoxic and
hypoglycemic

conditions,

yet

the

precise

mechanisms

underlying

this

susceptibility are unknown (Lyons and Kettenmann 1998).
HUCB cell therapy is an emerging treatment for CNS injury.

The

immaturity of HUCB cells contribute to the characteristic low immunogenicity
(Sanberg, Willing et al. 2005). HUCB cells are less immunogenic than other
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stem

cell

treatments

such

as

bone

marrow

and

thus

elicits

lower

immunomodulatory effects (Sanberg, Willing et al. 2005; Wang, Yang et al.
2009). In vivo, HUCB cells migrate to the site of injury, resulting in reduced
infarct volumes, neuroprotection and preservation of white matter following
MCAO (Vendrame, Cassady et al. 2004; Newman, Willing et al. 2005; Newcomb,
Ajmo et al. 2006; Hall, Guyer et al. 2009). Furthermore, multipotential stem cells
derived from HUCB cells secrete neuroprotective, angiogenic and antiinflammatory factors resulting in a functional recovery in spinal cord injuries
(Chua, Bielecki et al. 2010). In vitro experiments showed that in addition to
growth factors, HUCB cells secrete cytokines, matrix metalloproteinase inhibitors,
and interleukins (Neuhoff, Moers et al. 2007).

Additionally, HUCB cells co-

incubated with OLs reduced OGD-induced apoptosis by decreasing activated
caspase 3 (Hall, Guyer et al. 2009). Despite these potent protective actions and
known soluble factors, the precise pathways involved in HUCB cell-mediated OL
survival have yet to be elucidated.
The present study examined changes in the gene expression profiles of
primary OL cultures subjected to OGD to elucidate the protective pathways
induced by co-incubation with HUCB cells. Microarray results revealed that 33
genes were significantly increased in OLs co-incubated with HUCB cells and
exposed to OGD. The upregulation of the following genes were confirmed by
qRT-PCR: Uhmk1, Insig1, Mt3, Tspan2, Prdx4, Stmn2, MOG, and Vcan gene
expression.

Immunohistochemical analysis of tissues from rats treated with

HUCB cells 48 hrs after MCAO demonstrated increased protein expression of
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Uhmk1, Insig1, Mt3, Tspan2, Prdx4, and MOG. Future experiments identifying
the mechanisms by which HUCB cells enhance the expression of protective
genes in OLs will provide insight into novel therapies to combat stroke-induced
white matter injury.

Results
Characterization of Mature OLs
Antibodies specific for NG2, O4 and MBP were utilized in double
immunofluorescence staining to determine OL developmental stage in vitro (Fig.
1). NG2 is a reliable marker throughout the course of OL differentiation in vitro,
while O4 is expressed by immature OLs.

Furthermore, the expression of

myelinating proteins such as MBP denotes the mature OL phenotype. Six hours
following PDGF-AA withdrawal, NG2 and O4 colocalized in OLs with immature
morphology as indicated by the relatively low number of processes (Fig. 1A).
MBP was not detected at this time point. By 36 hrs following PDGF-AA removal,
colocalization of NG2 and MBP (Fig. 1B) was evident in OL cultures. The
prominent upregulation of MBP and the increased number of OL processes at 36
hrs signifies the progression of OLs to the mature phenotype that is present in
the adult rat brain.

Secreted Factors from HUCB Cells Protect Mature OLs
Cell death is associated with LDH release through the plasma membrane,
and therefore media levels of LDH were measured to assess OL injury after OGD
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(Fig. 2). Media from OL cultures exposed to OGD showed significantly increased
LDH levels compared to that from normoxic controls (p < 0.01, n = 7).
Furthermore, HUCB cell treatment demonstrated oligoprotection. Media from OL
cultures co-incubated with HUCB cells and subjected to OGD showed
significantly reduced LDH levels relative to cultures subjected to OGD alone (p <
0.05, n = 7). Importantly, the fact that HUCB cells were separated from OLs by
transwell inserts indicates that HUCB cells exerted these protective effects
through the release of soluble factors rather than through direct cellular contact.

HUCB Cell Protection is Associated with Changes in Gene
Expression
Affymetrix microarray was utilized to detect changes in gene expression
elicited by HUCB cells that were co-incubated with OLs during OGD. Of the 33
genes detected, eight genes encoding proteins associated with OL proliferation,
survival, and repair functions were selected for further investigation (Table 1,
bold font): Uhmk1, Insig1, Mt3, Tspan2, Prdx4, Stmn2, MOG, and Vcan. Genes
listed in Table 1 exclude expressed sequence tags and exhibit fold changes ≥1.5
compared to OGD controls.

qRT-PCR Verification of Microarray Results
qRT-PCR was performed to validate gene expression data obtained by
microarray analysis.

RNA was collected from supplementary experiments in

which HUCB cell co-incubation rescued OLs subjected to 24 hrs OGD. qRT-
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PCR confirmed results obtained by microarray (Fig. 3). HUCB cell treatment
increased expression of all selected genes (Fig. 3A-H) when compared to OLs
subjected to OGD without HUCB cell treatment (p< 0.05).

In addition, OGD

reduced the expression of Mt3, Tspan2, and Stmn2 (Fig. 3D-F) relative to
normoxic controls (p< 0.05). HUCB cells also increased the gene expression of
MOG, Insig1, Prdx4, Mt3, Stmn2, and Vcan (Fig. 3A-D, F, H) under normoxic
conditions when compared to normoxia only controls. Furthermore, a trend was
also observed whereby HUCB cell treatment during OGD either maintained or
increased mRNA expression levels relative to those of normoxic controls for all
genes except Stmn2.

HUCB Cells Reduce Infarct Volume
Systemic administration of HUCB cells 48hrs post-stroke significantly
reduced infarct volume. The fluorochrome Fluoro-Jade was used to detect
degenerating neurons in coronal brain section taken from rats subjected to
MCAO and experimental groups that received HUCB cell treatment. HUCB cell
treatment 48 hrs post-stroke significantly reduced infarct volume as compared to
MCAO only groups at 72 and 96hrs post stroke (*p<0.05, #p<0.01 respectively
(Fig.4). Sham operated groups were not significantly different from HUCB cell
treated groups (p>0.05). Furthermore, brain tissues of HUCB cell treatment
groups remained intact whereas tissue sections of MCAO only groups were
fragile with signs of degradation.
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HUCB Cells Protect OLs In Vivo
HUCB cells were administered 48 hrs post-stroke and sections were
probed with anti-O4, a highly specific marker of OL cell bodies and processes
(Schachner, Kim et al. 1981; Sommer and Schachner 1982), to determine
whether this therapy provided oligoprotection (Fig. 5). O4 immunoreactivity was
ubiquitous throughout the ipsilateral external capsule in sections from animals
treated with HUCB cells (Fig. 5A) and localized to cell bodies throughout the
region (Fig. 5D). Sections from vehicle-treated and sham-operated rats also
showed O4 immunoreactive cells, though they were sparsely distributed when
compared to the ipsilateral hemisphere of HUCB cell treated rats (Fig. 5B,E).
Quantification of the percent area occupied by O4 immunoreactivity (Fig. 5C)
showed that O4 was significantly increased in the ipsilateral hemisphere of
animals that received HUCB cells relative to vehicle-treated and sham-operated
controls (p<0.01).

HUCB Cells Induce Protein Expression
To expand on the microarray data from OL cultures, immunohistochemistry was performed to determine whether increased OL gene
expression in vitro was consistent with increased gene product expression in vivo
in the white matter rich region of the external capsule (Fig. 6 shows selected
region). Experiments included sections from rats that were administered either
vehicle or HUCB cells 48 hrs post-MCAO and rats that were subjected to shamMCAO and received vehicle injections. Immunostaining was performed for the
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following proteins: Uhmk1 (Fig. 6), Prdx4, Mt3, MOG, Insig1, Tspan2, and Vcan
(Fig. 7). In general, sham-operated controls (Fig. 6E,F) showed nearly identical
staining patterns as vehicle-treated controls (Fig. 6C,D) with no apparent
differences in the expression of any proteins examined. While MOG (Fig. 7E,F)
and Vcan (Fig. 7K,L) immunoreactivity was present throughout the extracellular
space, immunoreactivity for all other proteins was restricted to cell bodies.
Quantification was performed by calculating the mean percent area for each
treatment group (Fig. 8). The contralateral hemisphere was utilized as an internal
control to adjust for ipsilateral brain swelling caused by edema. There was no
significant difference in the expression of any proteins when comparing shamoperated and vehicle-treated controls. Uhmk1, Prdx4, Mt3, MOG and Insig1 were
upregulated in rats treated with HUCB cells compared to sham-operated and
vehicle-treated controls (*p < 0.05, #p< 0.01), while Tspan2 and Vcan expression
were unchanged.

Protein Expression and Localization
Double-label immunofluorescent staining was performed on sections from
animals subjected to MCAO to characterize the cellular expression profile of the
identified proteins. RIP, CD11b and GFAP were used for labeling of OL,
microglia and astrocytes, respectively, in conjunction with antibodies raised
against Prdx4, Mt3, Uhmk1, and Insig1. RIP colocalized with Prdx4, Mt3, Insig1,
and Uhmk1. RIP staining was localized in OL membranes as does Insig1,
whereas, Prdx4 Mt3, and Uhmk1 labeled cytoplasmically (Fig 9). Although Prdx4
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did not colocalize with CD11b (Fig. 10A-C), Prdx4-positive cell bodies colocalized
with GFAP-positive cells that exhibited the classic hypertrophic, stellate
morphology indicative of reactive astrocytes (Fig. 10D-F). Neither CD11b nor
GFAP colocalized with Mt3, Uhmk1 or Insig1 (Fig. 11).

Comparison of Gene Promoter
The promoter regions of genes upregulated in OLs co-cultured with HUCB
cells during OGD were explored by Genomatix software. Common transcription
factor binding sites were identified and included: EVI1, MZF1, GATA1, NK6.1,
PAX6, Sox-5, and SRF (Table. 2).

These results suggest that the genes

identified by microarray are being transcriptionally elevated by similar signaling
pathways activated by the soluble factors secreted from the HUCB cells.

Discussion
The present study employed both in vitro and in vivo approaches to test
the efficacy of HUCB cells in reducing OL cell death and white matter injury,
respectively. LDH levels in media from OL cultures co-incubated with HUCB cells
during OGD were reduced relative to OL-only cultures. As previously reported by
Newcomb et al 2006. and Vendrame et al 2004,. here we report that HUCB cell
treatment 48 hrs post-stroke reduced infarct volume.

Separate experiments

showed that O4 immunoreactivity increased in the ipsilateral external capsule of
rats treated with HUCB cells 48 hrs after MCAO. Upregulation of this OL marker
was consistent with the previous report by Hall et al 2009. showing that HUCB
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cell treatment increased MBP immunoreactivity. Thus, HUCB cells not only
protect OLs from OGD-induced injury in vitro, but also upregulate the expression
of white matter-associated proteins after ischemia in vivo.
Based upon these data, further experiments were conducted to identify
the mechanisms by which HUBC cells confer protection. Gene expression
analysis of OL cultures subjected to OGD and treated with HUCB cells revealed
increased mRNA content of Uhmk1, MOG, Insig1, Mt3, Tspan2, Prdx4, Stmn2,
and Vcan. Additionally, the levels of Mt3, Prdx4, MOG, Insig1 and Uhmk1 gene
products were elevated in the ipsilateral external capsule of animals administered
HUCB cells 48 hrs after MCAO. Previous reports have demonstrated expression
of these proteins in OLs (Miyazaki, Asanuma et al. 2002; Jin, Lee et al. 2005;
Kursula 2008; Sim, Lang et al. 2008). Here, double-label immunohistochemistry
showed that the OL specific antibody RIP colocalizes with Prdx4, Mt3, Insig1 and
Uhmk1 whereas only Prdx4 colocalized with astrocytes, while none of the
proteins colocalized with microglia/macrophages.

Both the increased gene

expression in culture and the lack of colocalization with other glial cell types in
vivo demonstrates that HUCB cells injected into MCAO rats caused OLs seated
within the cerebral white matter to upregulate these proteins.
To our knowledge, this is the first study linking upregulated expression of
genes and gene products with the protective effects of HUCB cell therapy within
the context of OL susceptibility and white matter injury resulting from ischemia.
HUCB cell-induced upregulations in Prdx4 and Mt3 observed here are consistent
with the notion that HUCB cells provide protection to white matter by inducing
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OLs to express proteins that combat oxidative damage. Oxidative stress is a
major cause of OL cell death resulting from OGD (Dewar, Underhill et al. 2003).
The Prdx family of anti-oxidants exerts protective effects through peroxidase
activity, detoxifying a range of free radical-forming organic hydroperoxides
(Hofmann, Hecht et al. 2002). In particular, Prdx4 regulates the thromboxane A2
receptor, a receptor which is upregulated by oxidative stress and contribute to
oxidative injury upon activation (Valentin, Field et al. 2004).

Previous work

showed that thromboxane A2 expression was inhibited during oxidative stress by
Prdx4 over-expression (Giguere, Turcotte et al. 2007).

In addition, the Prdx

family has also been shown to undergo structural changes to engage in
chaperone activity in response to excessive oxidation (Jang, Lee et al. 2004).
This chaperone activity may be a necessary function in the recovery of
oxidatively damaged cells by preventing free radical-induced aggregation of
cytosolic proteins (Jang, Lee et al. 2004; Kang, Rhee et al. 2005).
Similarly, the antioxidant Mt3 exerts its effects through metal detoxification
and free radical scavenging activity (Hozumi, Inuzuka et al. 1998; Uchida, Gomi
et al. 2002; Hwang, Kim et al. 2008).

These mechanisms are of particular

relevance to the present study since iron is not only a critical co-factor in myelin
production, but is also highly reactive and can contribute to free radical formation
and lipid peroxidation (Braughler, Duncan et al. 1986; Connor and Menzies
1996).

Additionally, OLs possess low concentrations of the antioxidant

glutathione, and oxidative stress leads to increased iron-mediated production of
ROS (Juurlink 1997; Juurlink, Thorburne et al. 1998). Thus, the protective effects
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of HUCB cells likely result, at least in part, from the secretion of a factor or
factors that ultimately increase the expression of Mt3.
HUCB cell therapy has previously been shown to target the Akt signaling
pathway, as Akt inhibition diminishes the protective effects of HUCB cells
(Dasari, Veeravalli et al. 2008). Importantly, growth factors such as VEGF and
interleukins such as IL-6, which are secreted by HUCB cells, have also been
shown to activate Akt, leading to cell migration, angiogenesis, and cell survival
(Morales-Ruiz, Fulton et al. 2000; Six, Kureishi et al. 2002; Neuhoff, Moers et al.
2007; Wegiel, Bjartell et al. 2008). The present study identified several common
transcription factor binding sites within the promoter regions of the genes
identified by microarray.

In particular, EVI1, MZF1, and GATA1 transcription

occur downstream of PI3k/Akt activation (Yu, Chiang et al. 2005; Liu, Chen et al.
2006; Moeenrezakhanlou, Shephard et al. 2008), providing additional evidence
that Akt is an important upstream activator responsible for the oligoprotective,
anti-oxidant effects of HUCB cells. Taken together, these data show that HUCB
cells release factors that transduce signaling converging on Akt, thereby
increasing the transcription of oligoprotective genes.
In addition to combating oxidative stress, data here show that HUCB cell
treatment alters the expression of proteins involved in microtubule regulation.
The concerted actions of MOG and Stmn2 inhibit microtubule polymerization,
and Stmn2 was previously found to increase neurite outgrowth via this
mechanism (Riederer, Pellier et al. 1997; Johns and Bernard 1999; Chiellini,
Grenningloh et al. 2008). Thus, these data provide evidence that upregulated
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expression of MOG and/or Stmn2 acts to inhibit microtubule polymerization in
OLs, thereby increasing proliferation and/or migration and enhancing white
matter repair.
Indeed, previous findings showed that mature OLs retain the ability to
proliferate following injury (Wood and Bunge 1991). In addition to regulating
microtubule dynamics through the phosphorylation of Stmn2 (Belmont and
Mitchison 1996), Uhmk1 induces proliferation and cell cycle progression through
the phosphorylation of p27kip1(Nakamura, Okinaka et al. 2008). Interestingly,
Uhmk1 was also upregulated after MCAO in HUCB cell-treated rats. Here, the
observed elevations in both Uhmk1 and O4 expression support the notion that
HUCB cell therapy protects white matter injury by inducing OL proliferation via
this pathway.
HUCB cell therapy may also alleviate white matter injury through
replacement of important somatic and/or axonal membrane lipids that are
degraded in response to H-I injury. The OL axon sheath is rich in
glycosphingolipids and cholesterol (Simons and Trajkovic 2006). Insig1 is
degraded when cholesterol is depleted within a cell (Gong, Lee et al. 2006), and
hypoxia increases Insig1 expression through a mechanism mediated by hypoxia
inducible factor 1α (Nguyen, McDonald et al. 2007).

Thus, the elevations in

Insig1 likely reflect HUCB cell induction of cholesterol biosynthesis aimed at
remyelination or restoration of the cell membrane.
Although a role for HUCB cells in remyelination is also supported here by
increased O4 expression, future experiments are necessary to determine
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precisely which proteins are associated with restoration of the myelin sheath or
cell membrane viability in general. For example, Tspan2 is integrated into the
myelin sheath membrane following active myelination, while Vcan is involved in
OL migration, proliferation, and structural integrity (Birling, Tait et al. 1999;
Sheng, Wang et al. 2005). Tspan2 and Vcan mRNAs were upregulated in OL
cultures subjected to OGD and treated with HUCB cells, yet there was no
significant difference in protein expression in vivo after MCAO.

These data

suggest that although Vcan and Tspan may be capable of enhancing axonal
and/or plasma membrane viability in culture, the complex microenvironment
present in the stroked brain determines which genes are translated and trafficked
accordingly. Likewise, these differences in in vitro transcription and in vivo
translation highlight the importance of combining multiple approaches to
elucidate the protective pathways elicited by HUCB cells. Future studies
investigating these pathways will provide insight into the precise factors secreted
by HUCB cells that protect OLs and cerebral white matter following ischemia.

Experimental Procedure
Animal Care
All animal procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals with a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Florida.
Experiments were designed to minimize the number of animals required.
Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN),
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maintained on a 12 hr light/dark cycle (7 am – 7 pm) in a climate-controlled room,
and allowed access to food and water ad libitum. Neonatal rats birthed from
untimed-pregnant dams were used for in vitro experiments and 300-350 g male
rats were used for in vivo experiments. Measures taken to minimize pain and
discomfort are described in the subsequent methodology.

Mixed Glial Culture Preparation
Postnatal day 3 rat pups were decapitated, brains removed, and meninges
dissected away. Rat cortices were dissociated in a solution of 0.25% trypsin/2.21
mM EDTA, triturated, and pelleted.

The pellet was re-suspended in DMEM

(Mediatech, Manassas, VA) supplemented with 2.5% fetal bovine serum, 10%
horse serum, and 1% antibiotic/antimycotic (DMEM+). Trypan Blue exclusion
was used to assess cell viability. Cells were seeded (1.5 x 107) into poly-Llysine-treated 75 cm2 tissue culture flasks.

Media was changed with fresh

DMEM+ the following day and cultures were incubated for 8 days at 37°C
(Gottschall, Yu et al. 1995).

OL Culture Purification
Mixed glial cultures were mechanically shaken for 1 hr to separate
microglial cells from the OL/astrocyte monolayer and media was discarded.
Fresh DMEM+ was added and the flask was returned to the incubator for an
additional 2 days at 37°C. OLs were purified from mixed glial preparations by
shaking the preparations for 18 hrs to separate OLs and microglia from the
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astrocyte monolayer. The media was removed, the cells were pelleted and resuspended in DMEM+. Viable cells were then counted using Trypan Blue
exclusion.

Microglia- and OL-containing media was added to 10 cm plastic

tissue culture dishes at a density of 107 cells/dish and incubated for 15 min at
37°C (procedure repeated 3 times for microglial adherence to the plastic). After
incubation, the dishes were gently swirled and media collected. The remaining
suspension was pelleted, re-suspended in DMEM+, and plated on glass poly-Llysine-treated coverslips at 3 x 105 cells/coverslip (McCarthy and de Vellis 1980).
The following day, media was changed to Neurobasal complete (Neurobasal
supplemented with B-27, L-glutamine 0.5mM, and 10ng/ml PDGF AA) (Barres,
Schmid et al. 1993; Yang, Watanabe et al. 2005). OLs remained in Neurobasal
complete and PDGF-AA for 7 days to encourage proliferation.

After the

proliferation period, PDGF-AA was withdrawn for 5 days to induce OL
differentiation into the mature phenotype (Yang, Watanabe et al. 2005).
Experiments were conducted immediately following the 5 day PDGF-AA
withdrawal. All in vitro experiments were conducted using > 95% pure OL
cultures, as previously described in (Hall, Guyer et al. 2009).

Oxygen Glucose Deprivation
OLs were seeded onto glass coverslips and randomly assigned to one of
two conditions:

OGD (DMEM without glucose) or normoxia (DMEM with

glucose). Transwell inserts (0.2 µm: Nalge Nunc International, Rochester, NY)
were added to 6-well plates containing coverslips. The inserts provided a barrier
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that prevented OL-HUCB cell contact but was permeable to media and soluble
factors. Cryopreserved HUCB cells (ALLCELLS, Emeryville, CA) were rapidly
thawed, washed, pelleted to remove the cryopreservatives and re-suspended in
10 ml DMEM with glucose and DNase (Sigma-Aldrich, St. Louis, MO; 50 kunitz
units/ml). HUCB cells were seeded onto tissue culture inserts (1x105 cells/insert)
and placed into the wells containing OL coverslips immediately prior to OGD
exposure. Experimental groups not subjected to HUCB cell treatment received
inserts containing an equal volume of DNase-supplemented DMEM with glucose.
A negative control of media alone and wells containing 1x105 HUCB cells with
DNase were included as controls to quantify HUCB cell contribution to the LDH
assay for each experimental condition.
Cells undergoing OGD were placed in an air-tight hypoxica chamber. The
chamber was then flushed with hypoxic gas (95% N2, 4% CO2, 1% O2; Airgas,
Tampa, FL) for 15 min and sealed for the duration of exposure. Normoxic cells
were maintained in a standard tissue culture incubator. Cultures were subjected
to OGD or normoxia for 24 hrs at 37°C. The media from each well was collected,
clarified by centrifugation, and LDH analysis was performed immediately.

LDH Assay
OL cell death in culture was determined using the LDH assay (Takara Bio,
Inc., Madison, WI). Briefly, 100 µl of tissue culture media from each experimental
group was added to a 96-well plate and 100µl of LDH reagent was added to each
well. Plates were incubated for 30 min at 25°C and absorbances were read on a
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microplate reader at a 548 nm wavelength. The media from HUCB cell only
cultures served as a control for HUCB cell death. The absorbance of HUCB cell
only media, as well as the absorbance of media only, was subtracted from the
total absorbance of the OL wells to eliminate background LDH activity.

RNA Collection and Purification
All collection and purification steps were performed under nuclease-free
conditions using DNAse/RNAse-free materials. For RNA lysate collection, 10 µl
of β-Mercaptoethanol (Pharmacia Biotech, Uppsala, Sweden) was added to 1 ml
RTL buffer (Qiagen Inc., Valencia, CA) and 350µl of the resulting mixture was
added to each OL-containing well to lyse the cells.

Cell lysates were then

collected and stored at -80°C prior to extracting the RNA. Qiagen’s RNeasy Mini
Kit was used to extract total RNA from each cell lysate using the optional Qiagen
RNase-Free DNase set for DNase digestion (Qiagen Inc).

Following the

extraction, 1µl of each RNA sample was tested in an Agilent 2100 Bio-analyzer to
determine the purity and quantity of RNA present. The remaining sample was
stored at -80°C for subsequent use with gene array.

Gene Array
Gene array was performed by the H. Lee. Moffitt Cancer Center
Microarray Core Facility utilizing a GeneChip 3000 Scanner, GCOS 1.4 with an
Affymetrix MAS 5.0 algorithm to generate signal intensities, and GeneChip Rat
Genome 230 2.0 Array (Affymetrix inc, Santa Clara, CA). Microarray data were
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normalized to RNA from cultures exposed to OGD. Only genes with
≥ 1.5 fold
increase and a signal intensity of > 100 were selected for further investigation.
For investigated treatment groups, samples were pooled (n=5) to obtain the
necessary RNA quantity and quality to perform this procedure.

Quantitative Real Time Polymerase Chain Reaction
Primers were ordered for selected sequences in which expression of
genes deemed vital to OL survival and proliferation were increased at least 1.5
fold after HUCB cell treatment. Uhmk1, Insig1, Mt3, Tspan2, Prdx4, Stmn2, and
MOG were purchased from SABiosciences (Frederick, MD; sequences are
proprietary). Vcan (Integrated DNA Technologies Coralville, IA) was examined
using the following primers:
Reverse 5’ TTT TAG GCA TTG CCC ATC TC
Forward 5’ ATG ACG TCC CCT GCA ACT AC
Total RNA (10 ng/µl) from OL cultures were subjected to qRT-PCR. The
RT reaction mixture consisted of 3µl Oligo (dT) Primers, 10 µl cDNA Synthesis
Master Mix (2X), 1 µl of Affinity Script RT/RNase Block enzyme mixture, and
RNase-free H2O to a total volume of 20 µl (Stratagene, La Jolla, CA).

The

reaction was incubated at 25°C for 5 min to allow primer annealing, then
incubated at 42°C for 45 min to allow cDNA synthesis followed by 5 min
incubation at 95°C to terminate the cDNA synthesis reaction.
Complementary DNA from the RT reaction was added to a PCR reaction
mix consisting of 1 µl cDNA, 12.5 µl 2X Brilliant 490 SYBR Green QPCR Master
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Mix (Stratagene), 2 µl primer, and nuclease-free PCR grade H2O to a total
volume of 25 µl. The samples were amplified using a BioRad ICycler (Bio-Rad
Laboratories, Hercules, CA) with the following protocol: heating to 95°C for 15
min followed by 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55
°C, and 30 sec of elongation at 72°C. GADPH was selected as a reference gene
and was used to calculate the mean normalized expression.

Determination of Promoter Response Elements
Accession numbers of OL genes shown by microarray and confirmed by
qRT- PCR to increase expression were entered into Genomatix software
(ElDorado/Gene2Promoter v4.7.0;Genomatix Software Inc, Ann Arbor, MI). The
promoter regions of selected genes were investigated for common transcription
factor binding sites.

Transcription factor families were determined and

transcription factor binding sites conserved across the promoter regions of all
selected genes were identified.

Laser Doppler Blood Flow Measurement
Prior to MCAO surgery, animals were anesthetized with 5% isofluorane/O2
in an induction chamber. Rats were treated prophylactically with Ketoprofen (10
mg/kg s.c.), atropine (0.25 mg/kg s.c.) and Baytril (20 mg/kg i.m.) in accordance
with IACUC guidelines. Ketoprofen injections were continued 3 days post-MCAO
to minimize pain and discomfort. A constant flow of anesthesia was supplied
with an interfaced scavenging system (3-4% isofluorane, flow rate 1 L/min)
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throughout the procedure. For Doppler insertion, the head was shaved and an
incision was made lateral to the midline of the dorsal plates of the skull. The skin
was spread and tissue covering the skull bone was pushed aside with a cottontipped applicator. Using a micro-drill, a small hole was drilled into the skull at 1
mm posterior and 4 mm lateral to bregma. A hollow stainless steel guide screw
was positioned into the hole and a fiber optic filament (500 µm) was inserted
through the screw guide and secured with Vetbond (3M, St. Paul, MN). Blood
perfusion in the brain was monitored using the Moor Instruments (Devon,
England) Ltd laser Doppler with Moor LAB proprietary Windows-based software.
When surgery was complete, the screw guide was removed, bone wax placed in
the burr hole and the scalp incision was sutured. Rats that did not show ≥ 60%
reduction in blood perfusion during MCAO were excluded from the study (Hall,
Guyer et al. 2009)

MCAO and HUCB Cell Treatment
MCAO surgeries were performed as previously described (Butler, Kassed
et al. 2002; Vendrame, Cassady et al. 2004; Hall, Guyer et al. 2009). Following
implantation of the Doppler probe, the external carotid artery was exposed and
isolated from the vagus nerve using blunt dissection. The artery was then ligated
and transected near the bifurcation of the internal and external carotid arteries.
The stump of the external carotid was then used as a guide to advance a
monofilament through the internal carotid to the origin of the middle cerebral
artery. The filament was then sutured secure and the incision closed. For sham
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surgeries, the Doppler probe was inserted and the external carotid exposed, but
no filament inserted.
To determine whether HUCB cells were protective against stroke-induced
injury, rats were injected (i.v, penile vein) with either HUCB cells (1x106 HUCB
cells in 500 PBS (pH 7.4 + DNase) or vehicle (500 μL PBS + DNase only) 48 hrs
after MCAO surgery. Sham-operated animals also received vehicle.

Animals

were then sacrificed 54, 72 and 96 hrs post-stroke and transcardially perfused
with 0.9% NaCl followed by 4% paraformaldehyde in PBS. The brains were
removed and saturated with 4% paraformaldehyde in PB followed by increasing
concentrations of sucrose in PBS (20%, 30%). Brains were then sectioned at 30
μm on a cryostat to include bregma 1.7mm through bregma -3.3, thaw mounted
onto slides and stored at -20°C.

Fluoro-Jade Histochemistry
Brain sections were thawed, dried and rehydrated with 100% EtOH for 3
min, 70% EtOH for 1min, and 1min in ddH2O. Using a 0.06% KMnO4 solution,
sections were oxidized for 15 min. After 3x1min washes in ddh20, brain sections
were placed in a 0.001% solution of Fluoro-Jade (Histochem, Jefferson, AR) in
0.1% acetic acid for 30 min. Following incubation, sections were washed 4x3min
in ddH2O, dried, cleared in xylene, and cover-slipped with DPX mounting medium
(VWR International Ltd, Poole, England).
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Immunohistochemistry
For peroxidase detection, brain tissue sections were washed with PBS for
5 min and incubated in 3% hydrogen peroxide for 20 min. Sections were then
washed 3 times in PBS, incubated for 1 hr in permeabilization buffer (2% serum,
0.3% Triton X-100 and 0.3% 1M lysine in PBS) and incubated overnight at˚C
4
with primary antibody in antibody solution (2% goat serum, 0.3% Triton X-100 in
PBS). The following day, sections were washed with PBS and incubated 1 hr at
room temperature with secondary antibody in antibody solution (2% serum, 0.3%
Triton X-100 in PBS). Sections were then washed in PBS, incubated in AvidinBiotin Complex (ABC; Vector Laboratories Inc, Burlingame, Ca) mixture for 1hr,
washed again and visualized using a DAB/peroxide solution (Vector Laboratories
Inc). After 3 final washes, sections were dried, dehydrated with increasing
concentrations of EtOH (70%, 95%, 100%), cleared with xylene and coverslipped with DPX. Antibodies consisted of the following:

mouse anti-MOG

(Abcam, Cambridge, MA; 1:250), rabbit anti-Uhmk1 (Protein tech group, Chicago
IL; 1:50), rabbit anti-Prdx4 (Abcam; 1:250), goat anti-Vcan (Santa Cruz
Biotechnology Inc, Santa Cruz, CA; 1:50), rabbit anti-Tspn2 (Sigma-Aldrich), goat
anti-Insig1 (Santa Cruz Biotechnology Inc; 1:50), and rabbit anti-Mt3 (SigmaAldrich; 1:50). Secondary detection was achieved using biotinylated secondary
antibodies (Vector Laboratories; 1:300) corresponding to the respective species
of primary antibodies.
For fluorescent labeling, tissue sections and cultured OLs were subjected
to the same method used for peroxidase detection, prior to the secondary
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antibody incubation, except that fluorescence samples were not incubated in
hydrogen peroxide. Double-label immunohistochemistry was achieved by coincubating the tissues or cells with primary antibodies raised in two distinct
species, followed by co-incubation with secondary antibodies conjugated to
distinct fluorophores. Following secondary antibody incubation, sections were
washed and cover-slipped using VectaShield Hard Set with DAPI (Vector
Laboratories). Antibodies used for fluorescent detection consisted of the
following: mouse anti-RIP (Millipore, Temecula, CA; 1:5000), rabbit anti-Prdx4
(Abcam; 1:500), mouse anti-O4 (Chemicon, Temecula, CA; 1:1000), mouse antiOX-42 (AbD Serotec, Kidlington, Oxford, UK; 1:1000), rat anti-MBP (Abcam;
1:1000), rabbit anti-NG2 (Chemicon; 1:500), rabbit anti-Uhmk1 (Protein tech
group; 1:50), goat anti-Insig1 (Santa Cruz Biotechnology Inc; 1:50), rabbit antiMt3 (Sigma-Aldrich; 1:50),

and mouse anti-GFAP (Chemicon; 1:1000).

Secondary antibodies used were Alexa Fluor 488 and 594 (Molecular Probes,
Eugene, OR; 1:1000). Negative controls were labeled in the absence of primary
antibody corresponding with respective secondary, as discussed previously.

Image Analyses
For in vivo image analyses, brain sections from≥ 3 animals per group
were used.

Coronal brain sections encompassing the striatum (Bregma

coordinates +1.7 through -0.3) were taken from each animal.

Images were

generated using a Zeiss Axioskop2 microscope controlled by Openlab
(Improvision Ltd, Lexington, MA) software. Images were captured with a Zeiss
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Axiocam Color camera.

The ImageJ 1.410 program (National Institutes of

Health, USA) was used to measure relative total intensity ratios of ipsilateral vs.
contralateral hemispheres. Ratios were calculated for each animal due to
ipsilateral brain swelling caused by edema. The group mean total intensity ratio
for each experimental treatment group was used for comparisons across
treatments. Total intensity analysis was conducted where treatment groups were
blinded.

Statistical Analyses
Data from all experiments were quantified and analyzed using GraphPad
Prism 4.0 (GraphPad Software, La Jola, CA) software.

Main effects were

determined using one-way ANOVAs, followed by Dunnett’s post hoc tests to
detect significant differences across treatment groups. When two variables were
present, two-way ANOVAs were used followed by Bonferroni post hoc tests. A
“p” value < 0.05 was used as the threshold for significant differences.
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Figure 1. OLs Differentiate Into the Mature Phenotype. Photomicrographs
show immunofluorescent staining of OL cultures at selected time points following
PDGF-AA withdrawal. (A) 6 hrs after withdrawal, NG2 (red) and O4 (green)
colocalized in OLs that exhibited both bipolar and immature morphology, as
indicated by the lateralized orientation of processes and the relatively low
number of processes, respectively. (B) At 36 hrs, NG2-positive OLs (red)
expressed MBP (green) and contained greater numbers of processes, indicating
that this withdrawal period was sufficient for differentiation into the mature
phenotype. Scale bars = 50μm.
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Figure 2. HUCB Cells Decrease LDH Release From OLs Subjected to 24 hrs
OGD. Media from OL cultures subjected to OGD-only contained elevated levels
of LDH compared to media from normoxic controls, demonstrating OGD-induced
cellular injury. OL cultures subjected to OGD were rescued by co-incubation with
HUCB cells, as LDH release was reduced back to levels of normoxic controls (*p
< 0.01, n=7).
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Figure 3. Affymetrix Gene Array Fold Changes are Confirmed by qRT-PCR.
HUCB cell treatment of OLs exposed to 24 hrs OGD significantly increased gene
expression of MOG, Insig1, Prdx4, Mt3, Tspan2, Stmn2, Uhmk1 and Vcan (A-H)
as compared to OLs subjected to OGD alone (* p < 0.05, n = 5). Additionally,
HUCB cell treatment of OLs exposed to normoxia increased the expression of
MOG (A), Insig1 (B), Prdx4 (C), Stmn2 (F), and Vcan (H) as compared to nontreated normoxic controls (^ p < 0.05 n = 5). Under OGD conditions, OL
expression of Mt3 (D), Tspan2 (E) and Stmn2 (F) were significantly reduced in
non-treated cells compared to both normoxic groups (# p < 0.05, n = 5).
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Figure 4. HUCB Cells Reduce Infarct Volume. HUCB cells provide
neuroprotection when given systemically 48hrs post-stroke. Photomicrographs
depict Fluoro-Jade staining of coronal rat brain sections at time points 54, 72 and
96 hrs post-MCAO. Infarct volume remained constant in MCAO only groups at 54
hrs (A), 72 hrs (B), and 96 hrs (C) post MCAO. Whereas HUCB cell
administration reduced infarct volume at 72 hrs (E) and 96 hrs (F) post-stroke (*
p < 0.05, # p < 0.01, respectively n = 4) while not significantly different from sham
operated animals (G-I) (p > 0.05) at respective time points. Bar graph (G) shows
the percent volume quantification of the ipsilateral (stroked) hemisphere
compared to the contralateral (non-stroked) hemisphere for each group.
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Figure 5. HUCB Cells Rescue OLs of the External Capsule Following
Ischemic Insult. O4 immunoreactivity was abundant throughout the ipsilateral
external capsule of animals treated with HUCB cells 48 hrs post-MCAO (A, D).
Vehicle (B) and sham-operated (E) controls also expressed O4, though
immunoreactivity was sparsely distributed and less prominent compared to
HUCB cell-treated animals. Quantification showed that HUCB cell treatment
significantly increased O4 immunoreactivity relative to both vehicle-treated and
sham-operated controls (* p < 0.01, n = 3). Scales bar = 50 μm. Arrows points to
O4 positive staining.
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Figure 6. HUCB Cells Increase White Matter Uhmk1 Expression Following
Ischemic Insult. HUCB cell treatment (A,B) 48 hrs post-MCAO significantly
increased Uhmk1 expression in the ipsilateral hemisphere of the external capsule
compared to vehicle (C,D) and sham-operated (E, F) controls (* p < 0.05, n = 3).
Low magnification scale bars = 100 μm; high magnification inset scale bars = 20
μm.
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Figure 7. HUCB Cells Alter White Matter Protein Expression Following
Ischemic Insult. Photomicrographs show increased expression of Prdx4 (A),
Mt3 (C), MOG (E) and Insig1 (G) in the ipsilateral hemisphere of animals treated
with HUCB cells 48 hrs post-MCAO compared to vehicle-treated controls
(B,D,F,H, respectively). No differences were observed in the expression of
Tspan (I,J) or Vcan (K,L) in response to HUCB cell treatment. Scale bars = 50
μm. Arrows points to positive staining.
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Figure 8. Immunohistochemical Quantification of White Matter Protein
Expression. HUCB cell treatment 48 hrs post-MCAO resulted in increased
expression of Uhmk1 (A), Prdx4 (B), Mt3 (C), MOG (D), and Insig1 (E) in the
ipsilateral external capsule compared to vehicle-treated and sham-operated
controls (*p < 0.05, #p < 0.01 n = 3). No significant differences were detected for
Tspan2 (F) or Vcan (G).
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Figure 9. Prdx4, Uhmk1, Insig1 and Mt3 Colocalized With OL Marker RIP.
Photomicrographs depicts immunoflourescent double-labeling of OL specific
antibody RIP (A, D, G, J) and antibodies generated against Prdx4 (B), Mt3 (K),
Insig1 (E), and Uhmk1 (H). RIP and Insig1 are colocalized (F) in OL membranes,
whereas Prdx4 (C), Mt3 (L), and Uhmk1 (I) are cytoplasmically localized. Scale
bars
=
50
μm.
Arrows
points
to
positive
staining.
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Figure 10. Prdx4 is Expressed in Astrocytes but not Microglia/macrophages
Following Ischemic Insult. Double-label Immunohistochemistry for Prdx4 (A)
and CD11b (B) shows that Prdx4 is not expressed in CD11b-positive
microglia/macrophages (C) contained within the ipsilateral external capsule.
Prdx4 (E) and GFAP (D) colocalization shows astrocytic expression of Prdx4 (F)
within the white matter following ischemic insult. Scale bars = 100 μm.
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Figure 11. Mt3, Uhmk, and Insig1 are not Expressed in
Microglia/macrophages or Astrocytes Following Ischemic Insult.
Immunofluorescent double-labeling shows that while expression is evident in the
ipsilateral external capsule following MCAO, Mt3, Uhmk1, and Insig1 did not
colocalize with CD11b-positive microglia/macrophages (A, C, E) or GFAPpositive astrocytes (B, D, F). Scale bars = 50 μm.
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Table 1. HUCB Cell Treatment Alters Gene Expression in OLs Subjected to
24 hrs OGD. Table shows OL genes for which HUCB cell treatment during OGD
caused a fold change ≥ 1.5 compared to non -treated OGD controls. Genes were
grouped based on functional relevance, and those associated with OL survival,
proliferation, and myelination (bold font) were selected for further investigation.
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Table 2. Common Transcription Factor Binding Sites Present in the
Promoters of Upregluated Genes. Table shows common transcription factor
binding sites identified in the promoter regions of Prdx4, Mt3, Insig1, MOG,
Uhmk1, Tspan2, Vcan and Stmn2. 8/8 denotes transcription factor binding sites
present in all 8 genes, whereas 7/8 denotes transcription factor binding sites
present in 7 of the 8 selected genes.
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CHAPTER THREE
HUMAN UMBILICAL CORD BLOOD CELLS PROTECT
OLIGODENDROCYTES FROM BRAIN ISCHEMIA THROUGH AKT SIGNAL
TRANSDUCTION

D.D. Rowe, MS, C.C. Leonardo, PhD, L.A. Collier, BS, A.E. Willing, PhD,
K.R. Pennypacker PhD.
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Abstract
Human umbilical cord blood (HUCB) cells protect against ischemic injury,
yet the mechanism of protection remains unclear. This study examined the role
of Akt activation in HUCB cell-mediated protection of oligodendrocytes (OLs). We
have employed the use of in vitro and in vivo models of ischemia to evaluate Akt
activation following HUCB cell treatment. As previously reported, HUCB cells
rescued cultured mature OLs from oxygen glucose deprivation (OGD) induced
cell

death,

as

measured

by

lactate

dehydrogenase

(LDH)

assay.

Immunohistochemical analysis showed that HUCB cell treatment enhanced Akt
phosphorylation in cultured OLs subjected to 24 hrs OGD. The addition of Akt
Inhibitor IV to cultured OLs abolished the protective effects of HUCB cells and
their induction of the antioxidant enzyme peroxiredoxin 4 (Prdx4). Systemic
administration of HUCB cells 48 hrs post middle cerebral artery occlusion
(MCAO) activated the Akt kinase through phosphorylation at serine 473, while
reducing proteolytic cleavage of caspase 3 in the ipsilateral external capsule.
These results demonstrate that Akt activation is an integral component of HUCB
cell mediated protection from ischemic injury.

Keywords
Stroke; white matter; human umbilical cord blood cells; ischemia; antioxidant; Akt activation, Caspase 3 activation.
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Abbreviations
HUCB, human umbilical cord blood; OL, oligodendrocyte; OGD, oxygen
glucose deprivation; LDH, lactate dehydrogenase; Prdx4, peroxiredoxin 4;
MCAO, middle cerebral artery occlusion; DMEM, dulbecco modified eagle
medium; PDGF-AA, platelet derived growth factor-AA; DMSO, dimethyl sulfoxide;
GADPH, glyceraldehyde-3-phosphate dehydrogenase; PBS, phosphate buffered
saline; RIP, Receptor interacting protein; Mt3, metallothionein 3; GDNF, glial cell
derived neurotrophic factor; BDNF, brain derived neurotrophic factor; LIF,
leukemia inhibitory factor; IL-1β, interleukin-1 beta; IL-6, interleukin-6; IGF1,
insulin like growth factor 1; VEGF, vascular endothelial growth factor; TIMP-1,
TIMP metallopeptidase inhibitor 1; BAD, bcl2 associated death promoter; PARP,
poly (ADP-ribose) polymerase; ROS, reactive oxygen species; RNS, reactive
nitrogen species.
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Introduction
Until recently, oligoprotection has been largely overlooked in the
development of new approaches to treat cerebral ischemia. Human umbilical
cord blood (HUCB) cells have been highly efficacious in treating experimental
stroke. HUCB cells rescued oligodendrocytes (OL)s subjected to oxygen glucose
deprivation (OGD) by increasing survival associated and antioxidant gene
expression while inhibiting apoptotic activators (Rowe, Leonardo et al. ; Hall,
Guyer et al. 2009). Moreover, HUCB cells reduced infarct volume, promoted
behavioral recovery and preserved white matter bundles following middle
cerebral artery occlusion (MCAO) (Vendrame, Cassady et al. 2004; Newman,
Willing et al. 2005; Hall, Guyer et al. 2009).
HUCB cells are comprised of proliferative hemopoietic colony-forming,
endothelial precursor and mesenchymal progenitor cells (Nakahata and Ogawa
1982; Nieda, Nicol et al. 1997; Erices, Conget et al. 2000). The protective
properties of this therapy have been attributed to the soluble factors secreted by
these cells, many of which are known activators of the Akt signal transduction
pathway (Kulik, Klippel et al. 1997; Jin, Mao et al. 2000; Newman, Willing et al.
2006; Neuhoff, Moers et al. 2007). Upon phosphorylation at serine 473, Akt
transduces cellular survival signals by inhibiting apoptotic cascades and
promoting activation of cell survival pathways. Indeed, previous studies have
shown that HUCB cell therapy protects cultured neurons from excitotoxic injury
through activation of Akt (Dasari, Veeravalli et al. 2008)
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Because converging lines of evidence demonstrate a role for Akt in the
protection of neural cells, the present study examined whether the protection
afforded to OLs by HUCB cell therapy occurs through Akt activation. Here we
report that HUCB cells rescued OLs and increased the expression of
peroxiredoxin 4 (Prdx4) in an Akt dependent manner. Immunohistochemical
analysis showed that systemic administration of HUCB cells increased Akt
phosphorylation and reduced proteolytic cleavage of caspase 3 following MCAO.
In summary, Akt activation is an integral and necessary transducer of HUCB cellmediated white matter protection.

Materials and Methods
Animal Care
All animal procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals with a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Florida.
Experiments were designed to minimize the number of animals required.
Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN),
maintained on a 12 hr light/dark cycle (6 am – 6 pm) in a climate-controlled room,
and allowed access to food and water ad libitum. Neonatal rats birthed from
untimed pregnant dams were used for in vitro experiments and 300-350 g male
rats were used for in vivo experiments.
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Mixed Glial Culture Preparation
Postnatal day 3 rat pups were decapitated, brains removed, and meninges
dissected away. Rat cortices were dissociated in a solution of 0.25% trypsin/2.21
mM EDTA, triturated, and pelleted.

The pellet was re-suspended in DMEM

(dulbecco modified eagle medium) (Mediatech, Manassas, VA) supplemented
with 2.5% fetal bovine serum, 10% horse serum, and 1% antibiotic/antimycotic
(DMEM+). Trypan Blue exclusion was used to assess cell viability. Cells were
seeded (1.5 x 107) into poly-L-lysine-treated 75 cm2 tissue culture flasks. Media
was changed with fresh DMEM+ the following day and cultures were incubated
for 8 days at 37°C (Gottschall, Yu et al. 1995).

OL Cultures Purification
Mixed glial cultures were mechanically shaken for 1 hr to separate
microglial cells from the OL/astrocyte monolayer and media was discarded.
Fresh DMEM+ was added and the flask was returned to the incubator for an
additional 2 days at 37°C. OLs were purified from mixed glial preparations by
shaking the preparations for 18 hrs to separate OLs and microglia from the
astrocyte monolayer. The media was removed, the cells were pelleted and resuspended in DMEM+. Viable cells were then counted using Trypan Blue
exclusion.

Microglia- and OL-containing media was added to 10 cm plastic

tissue culture dishes at a density of 107 cells/dish and incubated for 15 min at
37°C (procedure repeated 3 times for microglial adherence to the plastic). After
incubation, the dishes were gently swirled and media collected. The remaining
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OL suspension was pelleted, re-suspended in DMEM+, and plated on glass polyL-lysine-treated coverslips at 3 x 105 cells/coverslip (McCarthy and de Vellis
1980).

The following day, media was changed to Neurobasal complete

(Neurobasal supplemented with B-27, L-glutamine 0.5mM, and 10ng/ml PDGF
AA (Platelet derived growth factor AA) (Barres, Schmid et al. 1993; Yang,
Watanabe et al. 2005). OLs remained in Neurobasal complete and PDGF-AA for
7 days to encourage proliferation. After the proliferation period, PDGF-AA was
withdrawn for 5 days to induce OL differentiation into the mature phenotype
(Yang, Watanabe et al. 2005).

Experiments were conducted immediately

following the 5 day PDGF-AA withdrawal. All in vitro experiments were conducted
using > 95% pure OL cultures, as previously described in Hall et al 2009.

Oxygen Glucose Deprivation
OLs seeded onto glass coverslips were randomly assigned to one of two
conditions: OGD (DMEM without glucose) or normoxia (DMEM with glucose).
Akt inhibitor IV (10µM/ml; EMD4Biosciences, Gibbstown, NJ) was added to
media as treatment required.

Transwell inserts (0.2 µm; Nalge Nunc

International, Rochester, NY) were added to 6-well plates containing coverslips.
The inserts provided a barrier that prevented OL-HUCB cell contact but was
permeable to media and soluble factors.

Cryopreserved HUCB cells

(ALLCELLS, Emeryville, CA) were rapidly thawed, washed, pelleted to remove
the cryopreservatives and re-suspended in 10 ml DMEM with glucose and
DNase (50 kunitz units/ml; Sigma-Aldrich, St. Louis, MO).
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HUCB cells were

seeded onto tissue culture inserts (1x105 cells/insert) and placed into the wells
containing OL coverslips immediately prior to OGD exposure.

Experimental

groups not subjected to HUCB cell treatment received inserts containing an
equal volume of DNase-supplemented DMEM with glucose. A negative control
of media alone and wells containing 1x105 HUCB cells with DNase were included
as controls to quantify HUCB cell contribution to the LDH assay for each
experimental condition (Rowe, Leonardo et al.). Akt inhibitor IV was dissolved in
Dimethyl Sulfoxide (DMSO).

Akt inhibitor IV was placed in media of groups

receiving Akt inhibitor IV treatment at final concentration 10µM/ml. Experimental
groups not subjected to Akt inhibitor IV received equivalent quantity of DMSO.
Cells undergoing OGD were placed in an air-tight hypoxia chamber. The
chamber was then flushed with hypoxic gas (95% N2, 4% CO2, 1% O2; Airgas,
Tampa, FL) for 15 min and sealed for the duration of exposure. Normoxic cells
were maintained in a standard tissue culture incubator. Cultures were subjected
to OGD or normoxia for 24 hrs at 37°C. The media from each well was collected,
clarified by centrifugation, and lactate dehydrogenase (LDH) analysis was
performed immediately.

LDH Assay
OL cell death in culture was determined using the LDH assay (Takara Bio,
Inc., Madison, WI). Briefly, 100 µl of tissue culture media from each experimental
group was added to a 96-well plate and 100µl of LDH reagent was added to each
well. Plates were incubated for 30 min at 25°C and absorbances were read on a
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microplate reader at a 548 nm wavelength. The media from HUCB cell only
cultures served as a control for HUCB cell death. The absorbance of HUCB cell
only media, as well as the absorbance of media only, was subtracted from the
total absorbance of the OL wells to eliminate background LDH activity. A
standard curve was used to quantify OL cell death by extrapolating total numbers
of dead OLs from LDH values, as previously described (Rowe, Leonardo et al.).

RNA Collection and Purification
All collection and purification steps were performed under nuclease-free
conditions using DNase/RNase-free materials. For RNA lysate collection, 10 µl of
β-Mercaptoethanol (Pharmacia Biotech, Uppsala, Sweden) was added to 1 ml
RTL buffer (Qiagen Inc., Valencia, CA) and 350µl of the resulting mixture was
added to each OL-containing well to lyse the cells.

Cell lysates were then

collected and stored at -80°C prior to extracting the RNA. The Qiagen RNeasy
Mini Kit was used to extract total RNA from each cell lysate using the optional
Qiagen RNase-Free DNase set for DNase digestion (Qiagen Inc, Valencia, CA).
Following the extraction, 1µl of each RNA sample was tested in an Agilent 2100
Bio-analyzer to determine the purity and quantity of RNA present. The remaining
sample was stored at -80°C for subsequent use with gene array.

Quantitative Real Time Polymerase Chain Reaction
Primers

specific

to

Prdx4,

were

purchased

from SABiosciences

(Frederick, MD; sequences are proprietary). Total RNA (10 ng/µl) from OL
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cultures were subjected to qRT-PCR. The RT reaction mixture consisted of 3µl
Oligo (dT) Primers, 10 µl cDNA Synthesis Master Mix (2X), 1 µl of Affinity Script
RT/RNase Block enzyme mixture, and RNase-free H2O to a total volume of 20 µl
(Stratagene, La Jolla, CA). The reaction was incubated at 25°C for 5 min to allow
primer annealing, then incubated at 42°C for 45 min to allow cDNA synthesis
followed by 5 min incubation at 95°C to terminate the cDNA synthesis reaction.
Complementary DNA from the RT reaction was added to a PCR reaction
mix consisting of 1 µl cDNA, 12.5 µl 2X Brilliant 490 SYBR Green QPCR Master
Mix (Stratagene), 2 µl primer, and nuclease-free PCR grade H2O to a total
volume of 25 µl. The samples were amplified using a BioRad ICycler (Bio-Rad
Laboratories, Hercules, CA) with the following protocol: heating to 95°C for 15
min followed by 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55
°C, and 30 sec of elongation at 72°C.

Glyceraldehyde-3-phosphate

dehydrogenase (GADPH) was selected as a reference gene and was used to
calculate the mean normalized expression.

Laser Doppler Blood Flow Measurement
Prior to MCAO surgery, animals were anesthetized with 5% isofluorane/O2
in an induction chamber. Rats were treated prophylactically with ketoprofen (10
mg/kg s.c.), atropine (0.25 mg/kg s.c.) and Baytril (20 mg/kg i.m.) in accordance
with IACUC guidelines. Ketoprofen injections were continued 3 days post-MCAO
to minimize pain and discomfort. A constant flow of anesthesia was supplied
with an interfaced scavenging system (3-4% isofluorane, flow rate 1 L/min)
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throughout the procedure. For Doppler insertion, the head was shaved and an
incision was made lateral to the midline of the dorsal plates of the skull. The skin
was spread and tissue covering the skull bone was pushed aside with a cottontipped applicator. Using a micro-drill, a small hole was drilled into the skull at 1
mm posterior and 4 mm lateral to bregma. A hollow stainless steel guide screw
was positioned into the hole and a fiber optic filament (500 µm) was inserted
through the screw guide and secured with Vetbond (3M, St. Paul, MN). Blood
perfusion in the brain was monitored using the Moor Instruments (Devon,
England) Ltd laser Doppler with Moor LAB proprietary Windows-based software.
When surgery was complete, the screw guide was removed, bone wax placed in
the burr hole and the scalp incision was sutured. Rats that did not show
≥ 60%
reduction in blood flow during MCAO were excluded from the study (Hall, Guyer
et al. 2009).

Middle Cerebral Artery Occlusion
MCAO surgeries were performed as previously described (Butler, Kassed
et al. 2002; Vendrame, Cassady et al. 2004; Hall, Guyer et al. 2009). Following
implantation of the Doppler probe, the external carotid artery was exposed and
isolated from the vagus nerve using blunt dissection. The artery was then ligated
and transected near the bifurcation of the internal and external carotid arteries.
The stump of the external carotid was then used as a guide to advance a
monofilament through the internal carotid to the origin of the middle cerebral
artery. The filament was then sutured in place and the incision closed. For sham
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surgeries, the Doppler probe was inserted and the external carotid exposed, but
no filament inserted.

HUCB Cells Treatment
To determine whether HUCB cells were protective against stroke-induced
injury, rats were injected (i.v, penile vein) with either HUCB cells (1x106 HUCB
cells in 500 μL phosphate buffered saline (PBS) (pH 7.4 + DNase) or vehicle
(500 μL PBS + DNase) 48 hrs after MCAO surgery. Sham-operated animals
also received vehicle.
stroke

and

Animals were then euthanized 54, 72 and 96 hrs post-

transcardially

perfused

with

0.9%

NaCl

followed

by

4%

paraformaldehyde in PBS. The brains were removed and saturated with 4%
paraformaldehyde in PB followed by increasing concentrations of sucrose in PBS
(20%, 30%).

Brains were then sectioned at 30 μm on a cryostat to include

bregma 1.7mm through bregma -3.3mm, thaw mounted onto slides and stored at
-20°C.

Immunohistochemistry
For peroxidase detection, brain tissue sections/OL coverslips were
washed with PBS (pH 7.4) for 5 min and incubated in 3% hydrogen peroxide for
20 min. Sections were then washed 3 times in PBS, incubated for 1 hr in
permeabilization buffer (2% serum, 0.3% Triton X-100 and 0.3% 1M lysine in
PBS) and incubated overnight at 4̊C with primary antibody in antibody solution
(2% goat serum, 0.3% Triton X-100 in PBS). The following day, sections were
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washed with PBS and incubated 1 hr at room temperature with secondary
antibody in antibody solution (2% serum, 0.3% Triton X-100 in PBS). Sections
were then washed in PBS, incubated in Avidin-Biotin Complex (ABC; Vector
Laboratories Inc, Burlingame, Ca) mixture for 1hr, washed again and visualized
using a DAB/peroxide solution (Vector Laboratories Inc). After 3 final washes,
sections were dried, dehydrated with increasing concentrations of EtOH (70%,
95%, 100%), cleared with xylene and cover-slipped with DPX mounting medium
(VWR International Ltd, Poole, England). Antibodies consisted of the following:
rabbit anti-Phospho-Akt (Ser473) (1:50; Cell Signaling, Danvers, MA), rabbit antiCaspase 3 (1:1000; Sigma-Aldrich, St. Louis, MO). Secondary detection was
achieved using biotinylated secondary antibodies (1:300; Vector Laboratories)
corresponding to the respective species of primary antibodies.
For fluorescent labeling, tissue sections were not incubated in hydrogen
peroxide but otherwise subjected to the same method used for peroxidase
detection,

prior

to

the

secondary

antibody

incubation.

Double-label

immunohistochemistry was achieved by co-incubating the tissues with primary
antibodies raised in two distinct species, followed by co-incubation with
secondary antibodies conjugated to distinct fluorophores. Following secondary
antibody incubation, sections were washed and cover-slipped using VectaShield
Hard Set with DAPI (Vector Laboratories). Antibodies used for fluorescent
detection consisted of the following: mouse anti-RIP (1:5000; Millipore,
Temecula, CA), rabbit anti-Phospho-Akt (Ser473) (1:50; Cell Signaling), rabbit
anti-Caspase 3 (1:1000; Sigma-Aldrich). Secondary antibodies used were Alexa
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Fluor 488 and 594 (1:1000; Molecular Probes, Eugene, OR). Negative controls
were labeled in the absence of primary antibody corresponding with respective
secondary.

Image Analyses
Following in vitro experiments, images were generated using a Zeiss
Axioskop2 microscope controlled by Openlab (Improvision Ltd, Lexington, MA)
software. Images were captured with a Zeiss Axiocam Color camera. The
ImageJ 1.410 program (National Institutes of Health, USA) was used to measure
total staining intensity and was expressed as ratios of total intensity vs. number
of cells, thus showing the relative area positive staining per cell.
For in vivo image analyses, brain sections from≥ 3 animals per group
were used. Coronal brain sections encompassing the striatum (Bregma
coordinates +1.7 through -0.3) were taken from each animal.

Images were

generated using a Zeiss Axioskop2 microscope controlled by Openlab software.
Images were captured with a Zeiss Axiocam Color camera. The ImageJ 1.410
program was used to measure total staining intensity and was expressed as
percent ratios of ipsilateral vs. contralateral hemispheres. Ratios were calculated
for each animal to reduce the influence of edema in the brain hemisphere
ipsilateral to the infarct. The groups mean total intensity ratio for each
experimental treatment group was used for comparisons across treatments.
Total intensity analysis was conducted where experimenter was blinded of
treatment groups.
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Statistical Analyses
Data from all experiments were quantified and analyzed using GraphPad
Prism 4.0 (GraphPad Software, La Jola, CA) software. Main effects were
determined using one-way ANOVAs, followed by Dunnett’s post hoc tests to
detect significant differences across treatment groups. When two variables were
present, two-way ANOVAs were used followed by Bonferroni post hoc tests. A
“p” value < 0.05 was used as the threshold for significant differences.

Results
Akt Inhibition Negated HUCB Cell Protection In Vitro
To assess the role of Akt in HUCB cell protection, Akt inhibitor IV (10
µM/ml) was used to block Akt activation in OL cultures exposed to normoxia or
OGD in the presence or absence of the inhibitor (Figure 1). Exposure to 24 hr
OGD resulted in increased OL cell death as compared to normoxic control (n ≥ 6,
*p < 0.01), whereas HUCB cell co-incubation reduced OGD-induced cell death (n
≥ 6, #p < 0.05). The inhibition of Akt phosphorylation eliminated the protective
effects of HUCB cells, as cell death was elevated relative to HUCB only groups
and levels were similar to OGD only groups (p > 0.05). Significant differences
were not observed in OL cell death among the treatment groups exposed to
normoxic conditions (p > 0.05).
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HUCB Cells Increased Akt Phosphorylation In Vitro
Phosphorylation at serine 473 or threonine 308 is essential for Aktmediated cell survival (Zhao, Sapolsky et al. 2006). An antibody specific for Akt
phosphorylated at serine 473 was used to evaluate Akt phosphorylation of
cultured OLs (Figure 2). Exposure to 24 hrs OGD increased Akt phosphorylation
compared to normoxic control (n = 3, *p < 0.05).

HUCB cell treatment

significantly increased Akt phosphorylation relative to OGD alone (n = 3, #p <
0.05), whereas co-incubation of HUCB cell-treated OLs with Akt Inhibitor IV
reduced phosphorylation to levels detected under normoxic conditions (n = 3 p >
0.05). Akt phosphorylation was not different among treatment groups exposed to
normoxia (Figure 2 E, F, G, H, p > 0.05).

HUCB Cell-Induced Expression of Prdx4 is Suppressed by Akt
Inhibition In Vitro
We have previously reported that HUCB cells increased Prdx4 expression
in OLs exposed to OGD (Rowe, Leonardo et al.). To determine if Prdx4
expression is dependent on Akt activity, qRT-PCR was performed to quantify
expression of the Prdx4 gene transcript in OLs subjected to OGD and treated
with HUCB cells and/or Akt Inhibitor IV (Figure 3). As expected, HUCB cell
treatment increased Prdx4 mRNA when compared to OLs subjected to OGD
alone (n ≥ 7, *p < 0.05). Akt inhibiti on reduced Prdx4 mRNA expression both in
the presence and absence of HUCB cells (p > 0.05), and these levels were not
different from those observed in OLs subjected to OGD alone.
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Delayed HUCB Cell Treatment Increased Akt Phosphorylation
in Cerebral White Matter after MCAO
In vivo Akt phosphorylation was evaluated in the white matter rich region
of the external capsule. Rats received HUCB cells or vehicle 48 hrs after MCAO
or sham-MCAO and were euthanized at 54, 72 or 96 hrs post-stroke (Figure 4)
for immunochemistry. Constitutive phosphorylation was observed in shamoperated animals, and levels were not different from vehicle-treated rats at any of
the time points examined. HUCB cell treatment increased Akt phosphorylation at
72 hrs (E) and 96 hrs (H) relative to both vehicle controls and 54 hr HUCB celltreated rats (B) (n = 3, # p < 0.05 compared to 54 hr HUCB, * and ^p < 0.05
compared to 72 and 96 hr vehicle, respectively).

HUCB Cells Induce Prdx4 Expression in the External Capsule
Prdx4 expression was assessed to determine whether increased mRNA in
vitro was consistent with increased gene product expression in vivo (Figure 5).
Rats received HUCB cells or vehicle 48 hrs after MCAO or sham-MCAO and
were euthanized at 54, 72 or 96 hrs post-stroke for immunochemistry. Prdx4
immunoreactivity was restricted to cell bodies. In general, sham-operated
controls (Figure 5C,F, I) showed nearly identical staining patterns as vehicletreated controls (Figure 5A, D, G) with no apparent differences in Prdx4
expression over the time course examined. Quantification (Figure 5J) showed
that Prdx4 was upregulated in rats treated with HUCB cells compared to sham-
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operated and vehicle-treated controls at 72 hrs post MCAO (*p < 0.01), while no
differences were detected at 54 and 96 hrs.

P-Akt and Caspase 3 Co-localized with OL Marker RIP
Immunofluorescent staining was performed to determine whether
activated caspase 3 (MCAO vehicle-treated rats) (Figure 6 D-F) and
phosphorylated Akt (sham-operated rats) (Figure 6 A-C) expression localized to
OLs within the cerebral white matter. Anti-RIP was used to double-label OLs in
conjunction with antibodies raised against activated caspase 3 or phosphorylated
Akt. Both proteins were expressed by white matter OLs. Phosphorylated Akt was
evident in OL cytoplasm (Figure 6. C), whereas nuclear staining was observed in
micrographs depicting caspase 3/RIP co-localization (Figure 6. F).

HUCB Cell Treatment Reduces Caspase 3 Activation in the
External Capsule Following MCAO
The cleavage of caspase zymogens initiates and executes programmed
cell death. An antibody generated against activated caspase 3 was used to
identify apoptotic signaling in the external capsule of rats following MCAO (Figure
7). As expected, sections from sham-operated controls contained low levels of
activated caspase 3. In vehicle-treated animals, levels of activated caspase 3
were elevated at 54 and 72 hrs following MCAO compared to HUCB cell-treated
and sham-operated groups (n = 3, *p < 0.05, #p < 0.01 respectively). However,
caspase 3 activation returned to basal levels 96 hrs following MCAO in vehicle
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animals (n = 3, p > 0.05). Additionally, sections from HUCB cell-treated rats
showed no differences in caspase 3 levels compared to sham-operated rats
although caspase 3 positive staining was detected at 54hrs.

Discussion
Oligodendroglias are highly susceptible to ischemic injury (Pantoni, Garcia
et al. 1996; Lyons and Kettenmann 1998). In previous studies, soluble factors
from HUCB cells protected OLs from hypoxic injury by reducing caspase 3
activation and regulating proliferative, myelin-associated and antioxidant genes in
vitro (Rowe, Leonardo et al. ; Hall, Guyer et al. 2009). In vivo experiments have
demonstrated that HUCB cell therapy reduced infarct volume and preserved
cerebral white matter integrity; these effects occurred concomitantly with
increased expression of the antioxidant enzymes Prdx4 and metallothionein 3
(Mt3) (Rowe, Leonardo et al.). These experiments provided strong evidence that
the protection afforded by HUCB cell therapy occurs through the release of
soluble factors that induce antioxidant enzymes to reduce oxidative stress. Here,
data demonstrates that phosphorylation of Akt kinase is one mechanism
responsible for the oligoprotective, antioxidant properties of HUCB cell therapy.
Numerous factors secreted by HUCB cells have been shown to induce Akt
activation, including GDNF, BDNF, LIF, IL-1β, IL-6, IGF1, VEGF and TIMP-1
(Kulik, Klippel et al. 1997; Dolcet, Egea et al. 1999; Jin, Mao et al. 2000; Jin,
Omori et al. 2003; Lee, Yoo et al. 2003; Lentzsch, Chatterjee et al. 2004; Wegiel,
Bjartell et al. 2008). The pro-survival actions of Akt are well known. For example,
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cellular proliferation and survival have been shown to result from Akt-induced
phosphorylation of BAD, the forkhead related family of mammalian transcription
factors and glycogen synthase kinase 3β (Zhao, Sapolsky et al. 2006). In the
present study, HUCB cells rescued cultured OLs subjected to 24 hrs OGD,
whereas the addition of Akt Inhibitor IV completely blocked this effect. Similar
results were demonstrated by Dasari et. al., where the ability of HUCB cells to
rescue neurons from glutamate excitotoxicity was blocked by Akt inhibition. Thus,
the mechanism of oligoprotection observed after HUCB cell treatment is
consistent with previous findings and further supports the contention that soluble
factors activate Akt signal transduction to increase the viability of cells exposed
to ischemic conditions.
We also show that systemic treatment with HUCB cells at 48 hrs postMCAO increased Akt activation in the external capsule through phosphorylation
at serine 473. These data are in agreement with previous data showing that Akt
was rapidly phosphorylated at serine 473 following ischemia in vitro and in vivo,
specifically 1 hr following MCAO (Noshita, Lewen et al. 2001; Shibata, Yamawaki
et al. 2002; Zhao, Sapolsky et al. 2006). When Akt is unphosphorylated in
disease states such as stroke, apoptotic cascades are activated resulting in the
release of cytochrome c, caspase 3 and PARP (poly (ADP-ribose) polymerase)
cleavage, thus inducing cell death (Nicholson, Ali et al. 1995; Le Rhun, Kirkland
et al. 1998; Datta, Brunet et al. 1999; Yu, Andrabi et al. 2006; Zhao, Sapolsky et
al. 2006). In the present study, the HUCB cell-induced increase in Akt activation
was associated with decreased caspase cleavage, suggesting that HUCB cell
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treatment

attenuated

stroke-induced

caspase

activation

through

Akt

phosphorylation. Furthermore, the lack of phosphorylated Akt in the external
capsule of vehicle-treated animals at 96 hrs further supports the notion that
unphosphorylated Akt leads to increased cell death through apoptotic signaling.
Indeed, activated caspase 3 was abundant within the cerebral infarct of vehicletreated rats at this time point.
The formation of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) is also well characterized in ischemic models. These radicals and
their associated byproducts produce damage to lipid membranes (Cuzzocrea,
Riley et al. 2001), oxidation, methylation and depurination, producing DNA
breaks and mutations that lead to mitochondrial energy failure and subsequent
cell death (Steenken 1989; Routledge, Wink et al. 1994; Weitzman, Turk et al.
1994; Cuzzocrea, Riley et al. 2001). Prdx4 is an antioxidant enzyme that
detoxifies the cellular environment through peroxidase activity (Hofmann, Hecht
et al. 2002; Dewar, Underhill et al. 2003). Here, Akt inhibition arrested HUCB
cell-induced Prdx4 mRNA expression in OLs exposed to OGD. Additionally,
Prdx4 protein expression was significantly increased 24 hrs after HUCB cell
treatment in the white matter of rats subjected to MCAO, and these elevations
correlated with increased phosphorylated Akt.

Conclusions
Previous reports showed that administration of HUCB cells reduced
behavioral deficits and infarct volume after stroke and spinal cord injury (Saporta,
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Kim et al. 2003; Vendrame, Cassady et al. 2004; Newcomb, Ajmo et al. 2006;
Hall, Guyer et al. 2009; Chua, Bielecki et al. 2010), yet the precise mechanisms
underlying these protective effects remained unknown. The present study
identified a distinct pathway utilized by HUCB cell therapy to mediate protection.
Data show that Akt phosphorylation is required for oligoprotection and
upregulated expression of the Prdx4 gene transcript in vitro. Furthermore, Akt
phosphorylation is associated with neuroprotection, increased Prdx4 protein
expression and decreased caspase 3 activation in vivo. Taken together, these
data provide strong evidence that the effects of HUCB cells on oligoprotection,
antioxidant enzyme expression and caspase activity converge on Akt signaling.
Future studies investigating specific factors secreted by HUCB cells and the
pathways they activate will be instrumental in establishing more detailed
mechanisms of HUCB cell actions on OLs and the cerebral white matter following
ischemia.
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Figure 1. Akt Inhibition Negates the Protective Effects of HUCB Cells on
Cultured OLs. An increase in OL cell death was detected in cultures subjected
to 24 hr OGD compared to normoxic controls (n≥ 6, *p < 0.01), demonstrating
OGD-induced cellular injury. OL cultures subjected to OGD were rescued by coincubation with HUCB cells, as cell death was reduced back to levels present in
normoxic controls (n ≥ 6, #p < 0.05). Addition of Akt Inhibitor IV eliminated HUCB
cells oligoprotective effects in cultures exposed to 24hr ≥OGD
6). (n
Additionally, there was no effect of treatment on OLs exposed to normoxic
conditions.
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Figure 2. HUCB Cells Increase Akt Phosphorylation in OLs Subjected to
24hrs OGD. Immunohistochemistry was performed using an antibody generated
against Akt phosphorylated at serine 473. Micrographs show immunoreactivity in
OLs exposed to OGD (A-D) or normoxia (E-H). Treatment groups were vehicle
(A, E), HUCB cells (B, F), Akt Inhibitor IV (C, G) or HUCB cells + Akt Inhibitor IV
(D, H). Quantification (I) revealed increased Akt phosphorylation in OLs exposed
to OGD relative to normoxic controls (n = 3, *p < 0.05). Addition of HUCB cells
resulted in an additional increase in phosphorylation during OGD relative to
vehicle-treated OGD controls (n = 3, #p < 0.05). Akt Inhibitor IV reduced
phosphorylation during OGD when added in the presence or absence of HUCB
cells, such that immunoreactivity was not different from normoxic controls. Scale
bars = 50 μm.
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Figure 3. Akt Inhibitor IV Suppresses HUCB Cell Induced Prdx4 Expression
During OGD. qRT-PCR was performed to quantify mRNA expression of the
antioxidant enzyme Prdx4. OLs were subjected to OGD and treated with HUCB
cells in the presence or absence of Akt Inhibitor IV. HUCB cells increased Prdx4
gene transcript compared to vehicle-treated controls (n ≥ 7, *p < 0.05,). Co incubation of the Akt inhibitor with HUCB cells reduced the HUCB cell-induced
elevation in Prdx4 mRNA back to levels detected in OLs treated with vehicle or
Akt inhibitor alone.
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Figure 4. HUCB Cells Increase Akt Phosphorylation In Vivo.
Immunohistochemistry was performed using an antibody generated against Akt
phosphorylated at serine 473. Micrographs show immunoreactive cells (arrows)
in the ipsilateral external capsule of vehicle-treated (A, D, G), HUCB cell-treated
(B, E, H) and sham-operated (C, F, I) rats. These rats were euthanized at 54 (AC), 72 (D-F) or 96 hrs (G-I) after MCAO. Quantification (J) revealed increased
phosphorylation of Akt in tissues from HUCB cell-treated rats euthanized at 72
(^p < 0.05) and 96 hrs (*p < 0.05) compared to vehicle-treated rats at the
respective time points. Additionally, phosphorylated Akt was increased after
HUCB cell treatment at 72 hrs relative to 54 hrs (n = 3, #p < 0.05), while no
differences were detected between groups at the 54 hr time point. Scale bars =
50 μm.
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Figure
5.
HUCB
Cells
Induce
Prdx4
Expression
In
Vivo.
Immunohistochemistry was performed to determine the effects of HUCB cell
therapy on Prdx4 protein expression. Micrographs show immunoreactive cells
(arrows) in the ipsilateral external capsule of vehicle-treated (A, D, G), HUCB
cell-treated (B, E, H) and sham-operated (C, F, I) rats. These rats were
euthanized at 54 (A-C), 72 (D-F) or 96 hrs (G-I) after MCAO. Quantification (J)
revealed increased expression of Prdx4 in tissues from rats treated with HUCB
cells and euthanized at 72 hrs post-MCAO relative to vehicle-treated and shamoperated animals at the same time point (n=3. *p < 0.01). No differences were
detected across treatment groups at any other time points examined. Scale bars
= 50 μm.
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Figure 6. Akt and Caspase 3 are Activated in OLs In Vivo. Confocal
micrographs show immunoflourescent co-localization using the OL specific
antibody anti-RIP (A, D) in combination with antibodies generated against
phosphorylated Akt (B, MCAO sham-operated vehicle treated rat) or activated
caspase 3 (E, MCAO vehicle-treated rat) in the external capsule. Merged images
demonstrate expression of phosphorylated Akt (C) and activated caspase 3 (F) in
RIP-positive OLs. Arrows denote immunoreactivity. Scale bars = 50 μm.
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Figure 7. HUCB Cells Reduce Caspase 3 Activation In Vivo.
Immunohistochemistry was performed to determine the effects of HUCB cell
therapy on caspase 3 activation. Micrographs show immunoreactive cells
(arrows) in the ipsilateral external capsule of vehicle-treated (A, D, G), HUCB
cell-treated (B, E, H) and sham-operated (C, F, I) rats. These rats were
euthanized at 54 (A-C), 72 (D-F) or 96 hrs (G-I) after MCAO. MCAO induced
caspase 3 activation was detected 54 (A) and 72 hrs (D) post MCAO.
Quantification (J) revealed HUCB cell treatment blocked the stroke-induced
activation of caspase 3 detected in vehicle-treated rats at 54 and 72 hrs (n = 3,
*#p < 0.05) such that levels were not different from sham-operated controls. No
differences were detected across groups at the 96 hr time point. Scale bars = 50
μm.
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CHAPTER FOUR
LEUKEMIA INHIBITORY FACTOR AND GRANULOCYTE COLONY
STIMULATING FACTOR INDUCE ANTIOXIDANTS TO ENHANCE SURVIVAL
OF OLIGODENDROCYTES EXPOSED TO OXYGEN GLUCOSE
DEPRIVATION

D.D. Rowe, MS, J Recio, MS, L.A. Collier, BS, A.E. Willing, PhD,
K.R. Pennypacker, PhD.
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Abstract
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine with numerous
effects on cellular survival and function. Human umbilical cord blood (HUCB)
cells secrete soluble factors to protect neurons and oligodendrocytes (OL)s from
oxygen glucose deprivation (OGD). LIF is a soluble factor expressed and
secreted by HUCB cells. We investigated the effect of LIF on OLs exposed to 24
hrs oxygen glucose deprivation (OGD). Administration of LIF attenuated OGD
induced OL cell death by increasing expression of antioxidants metallothionein
(Mt3) and peroxiredoxin (Prdx4). The addition of an Akt inhibitor (Akt inhibitor IV)
abolished LIF protective effects and blocked LIF induced Prdx4 expression.
Granulocyte colony stimulating factor (GCSF) reduced OL cell death, an effect
that was blocked by Akt inhibitor. Additionally LIF/GCSF treatment did not reduce
cell death appreciable from LIF treatment alone. We have examined two soluble
factors secreted by HUCB cells and have shown that the optimization of each
monotherapy is just as efficacious as HUCB cell treatment in vitro.

Introduction
Following ischemic injury, the white matter alike the gray matter is
adversely affected by reduced cerebral blood flow. Neuronal death attributed to
ischemia has been extensively studied, but our knowledge of white matter
pathology following an ischemic insult remains limited. Oligodendrocytes (OL)s
predominate the white matter tract and of the glial cells are most susceptible to
ischemic injury (Lyons and Kettenmann 1998). This susceptibility has been linked
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to the inherently high metabolic rate, iron content and reduced antioxidant
production capacity of OLs (Braughler, Duncan et al. 1986; Connor and Menzies
1996; Juurlink 1997; Juurlink, Thorburne et al. 1998).
Cell based therapy has shown promise in stroke research, specifically
human umbilical cord blood (HUCB) cells. HUCB cells migrate to the infarct area,
reverse stroke induced pathology by rescuing neurons, glial cells and enhancing
behavioral recovery post stroke (Vendrame, Cassady et al. 2004; Vendrame,
Gemma et al. 2005; Hall, Guyer et al. 2009; Rowe, Leonardo et al. 2010). HUCB
cells attenuate stroke pathology in the white matter tract by halting the activation
and progression of apoptotic cascades and, increasing the expression of survival
associated proteins in OLs (Rowe, Leonardo et al. 2010). Although promising,
cell based therapies are difficult to standardize. Therefore, it is important to
understand the mechanism by which these cells mediate cellular survival and
behavioral recovery post stroke. HUCB cells secrete soluble factors to protect OL
exposed to oxygen glucose deprivation (Rowe, Leonardo et al. 2010). A number
of these soluble factors have been identified as cytokines, chemokines,
metalloproteinase inhibitors, growth factors and interleukins (Neuhoff, Moers et
al. 2007).
Leukemia inhibitory factor (LIF) is a 180 amino acid single 4-α-helix
glycoprotein that binds to the LIF cell surface receptor complex which includes
the LIF receptor β (LIFR) and the gp130 receptor chain (Kurek 2000; Metcalf
2003). LIF rescued OLs and reduced demyelination following spinal cord injury
through STAT 3 and PI3/Akt survival pathway activation (Metcalf and Gearing
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1989; Azari, Profyris et al. 2006). Furthermore intravenous administration of LIF
attenuated

demyelination

and

OL

loss

in

experimental

autoimmune

encephalomyelitis (EAE), the mouse model of multiple sclerosis, the addition of
antibodies generated against LIF exacerbated EAE disease pathology (Metcalf
and Gearing 1989; Metcalf and Gearing 1989; Butzkueven, Zhang et al. 2002). In
ischemic conditions, increased LIF was detected in neuronal cell bodies and
axons of rats subjected to MCAO. Where in cultures, LIF expression was
upregulated in astrocytes exposed to OGD (Slevin, Krupinski et al. 2008).
Furthermore, intracerebral injections of LIF following focal ischemia attenuated
ischemic brain injury (Suzuki, Yamashita et al. 2005). Specifically in culture, LIF
administration rescued mature OLs from the pro inflammatory cytokines
interferon γ and tumor necrosis factor α induced cell death, through the activation
of both JAK/STAT and PI3/Akt pathway (Slaets, Dumont et al. 2008).
GCSF is a 19.6 kDa glycoprotein that alike LIF and other HUCB cell
secreted factors activate the Akt pathway (Nagata, Tsuchiya et al. 1986; Hunter
and Avalos 1998; Neuhoff, Moers et al. 2007; Slaets, Dumont et al. 2008).
Specifically in stroke, GCSF has been shown to be neuroprotective (Solaroglu,
Cahill et al. 2006). Following MCAO, GCSF administration reduced the
inflammatory response to stroke. This study highlighted the down regulation of
nuclear factor kappa B (NFκB) and inducible nitric oxide synthase (iNOS) in the
infarct area (Sehara, Hayashi et al. 2007). Additionally, in a small study
conducted in 2006 GCSF was proven safe and effective at improving neurologic
outcomes in patients who experienced strokes affecting the MCA (Shyu, Lin et al.
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2006). Furthermore, a more recent study (Ax 200) has been completed and the
results are being prepared for publication.
In this study, we examined whether LIF can duplicate HUCB cell
protective effects. We report that LIF attenuated OGD induced OL cell death in
vitro where the addition of Akt inhibitor IV blocked LIF protection. As with HUCB
cell experiments, administration of LIF upregulates antioxidants Prdx4 and Mt3
resulting in reduced oxidative stress. Examining another soluble factor secreted
by HUCB cells, administration of granulocyte colony stimulating factor (GCSF)
rescued OL subjected to 24 hrs OGD and again Akt inhibitor IV blocked GCSF
effects. Thus, HUCB cells release at least two soluble factors that promote
oligoprotection via Akt and antioxidant enzyme activity.

Materials and Methods
Animal Care
All animal procedures were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals with a protocol approved by the
Institutional Animal Care and Use Committee at the University of South Florida.
Experiments were designed to minimize the number of animals required.
Sprague-Dawley rats were purchased from Harlan Labs (Indianapolis, IN),
maintained on a 12 hrs light/dark cycle (7 am – 7 pm) in a climate-controlled
room, and allowed access to food and water ad libitum. Neonatal rats birthed
from untimed-pregnant dams were used for in vitro experiments and 300-350 g
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male rats were used for in vivo experiments. Measures taken to minimize pain
and discomfort are described in the subsequent methodology.

Mixed Glial Culture Preparation
Postnatal day 3 rat pups were decapitated, brains removed, and meninges
dissected away. Rat cortices were dissociated in a solution of 0.25% trypsin/2.21
mM EDTA, triturated, and pelleted.

The pellet was re-suspended in DMEM

(Mediatech, Manassas, VA) supplemented with 2.5% fetal bovine serum, 10%
horse serum, and 1% antibiotic/antimycotic (DMEM+). Trypan Blue exclusion
was used to assess cell viability. Cells were seeded (1.5 x 107) into poly-Llysine-treated 75 cm2 tissue culture flasks.

Media was changed with fresh

DMEM+ the following day and cultures were incubated for 8 days at 37°C
(Gottschall, Yu et al. 1995).

OL Cultures Purification
Mixed glial cultures were mechanically shaken for 1 hr to separate
microglial cells from the OL/astrocyte monolayer and media was discarded.
Fresh DMEM+ was added and the flask was returned to the incubator for an
additional 2 days at 37°C. OLs were purified from mixed glial preparations by
shaking the preparations for 18 hrs to separate OLs and microglia from the
astrocyte monolayer. The media was removed, the cells were pelleted and resuspended in DMEM+. Viable cells were then counted using Trypan Blue
exclusion.

Microglia- and OL-containing media was added to 10 cm plastic
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tissue culture dishes at a density of 107 cells/dish and incubated for 15 min at
37°C (procedure repeated 3 times for microglial adherence to the plastic). After
incubation, the dishes were gently swirled and media collected. The remaining
suspension was pelleted, re-suspended in DMEM+, and plated on glass poly-Llysine-treated coverslips at 3 x 105 cells/coverslip (McCarthy and de Vellis 1980).
The following day, media was changed to Neurobasal complete (Neurobasal
supplemented with B-27, L-glutamine 0.5mM, and 10ng/ml PDGF AA) (Barres,
Schmid et al. 1993; Yang, Watanabe et al. 2005). OLs remained in Neurobasal
complete and PDGF-AA for 7 days to encourage proliferation.

After the

proliferation period, PDGF-AA was withdrawn for 5 days to induce OL
differentiation into the mature phenotype (Yang, Watanabe et al. 2005).
Experiments were conducted immediately following the 5 day PDGF-AA
withdrawal. All in vitro experiments were conducted using > 95% pure OL
cultures, as previously described in (Hall, Guyer et al. 2009).

Oxygen Glucose Deprivation
OLs were seeded onto glass coverslips and randomly assigned to one of
two conditions:

OGD (DMEM without glucose) or normoxia (DMEM with

glucose). LIF/GCSF (Millipore, Billerica, MA: 10-1000ng/ml) was added to media
as treatment required.

Akt inhibitor IV (EMD4Biosciences, Gibbstown, NJ:

10µM/ml) was added to media as treatment required. Experimental groups not
subjected to LIF treatment an equal volume of buffer which LIF was dissolved in
(50mM sodium phosphate/1mMDTT/10% glycerol/250mM Nacl, pH 7.4 and
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0.02% Tween 20) supplemented DMEM. A negative control of media alone and
wells containing LIF or GCSF were included as controls to quantify media and
buffer solution contribution to LDH assay for each experimental condition. Akt
inhibitor IV was dissolved in DMSO. Akt inhibitor IV was placed in appropriate
media at final concentration 10µM/ml. DMSO was added to medium in
experimental groups not subjected to Akt inhibitor IV.
For treatment with HUCB cells, Transwell inserts (0.2 µm; Nalge Nunc
International, Rochester, NY) were added to 6-well plates containing coverslips.
The inserts provided a barrier that prevented OL-HUCB cell contact but are
permeable to media and soluble factors.

Cryopreserved HUCB cells

(ALLCELLS, Emeryville, CA) were rapidly thawed, washed, pelleted to remove
the cryopreservatives and re-suspended in 10 ml DMEM with glucose and
DNase (50 kunitz units/ml; Sigma-Aldrich, St. Louis, MO).

HUCB cells were

seeded onto tissue culture inserts (1x105 cells/insert) and placed into the wells
containing OL coverslips immediately prior to OGD exposure.

Experimental

groups not subjected to HUCB cell treatment received inserts containing an
equal volume of DNase-supplemented DMEM with glucose. A negative control
of media alone and wells containing 1x105 HUCB cells with DNase were included
as controls to quantify HUCB cell contribution to the LDH assay for each
experimental condition (Rowe, Leonardo et al. 2010). Groups containing LIF
neutralizing antibody received antibody with respective controls (10µg/ml; R&D
Systems, Minneapolis, MN)
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Cells undergoing OGD were placed in an air-tight hypoxia chamber. The
chamber was then flushed with hypoxic gas (95% N2, 4% CO2, 1% O2; Airgas,
Tampa, FL) for 15 min and sealed for the duration of exposure. Normoxic cells
were maintained in a standard tissue culture incubator. Cultures were subjected
to OGD or normoxia for 24 hrs at 37°C. The media from each well was collected,
clarified by centrifugation, and LDH analysis was performed immediately.

LDH Assay
OL cell death in culture was determined using the LDH assay (Takara Bio,
Inc., Madison, WI). Briefly, 100 µl of tissue culture media from each experimental
group was added to a 96-well plate and 100µl of LDH reagent was added to each
well. Plates were incubated for 30 min at 25°C and absorbances were read on a
microplate reader at a 548 nm wavelength.

The media from LIF only wells

served as a control for absorbance as a result of LIF. The absorbance of LIF only
media, as well as the absorbance of media only, was subtracted from the total
absorbance of the OL wells to eliminate background LDH activity. A standard
curve was used to quantify OL cell death by extrapolating total numbers of dead
OLs from LDH values, as previously described in Rowe et.al.

SOD Activity
SOD activity in culture was determined using the SOD Assay (Kamiya
Bomedical, Seattle, WA). Tissue culture media from each experimental group
and supplied reagents were added to a 96 well plate as directed by
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manufacturer. Plates were incubated for 25 min at 25°C and absorbances were
read on a microplate reader at a 450 nm wavelength. SOD activity was
determined from recorded absorbances using the equation provided by
manufacturer.

RNA Collection and Purification
All collection and purification steps were performed under nuclease-free
conditions using DNAse/RNAse-free materials. For RNA lysate collection, 10 µl
of β-Mercaptoethanol (Pharmacia Biotech, Uppsala, Sweden) was added to 1 ml
RTL buffer (Qiagen Inc., Valencia, CA) and 350µl of the resulting mixture was
added to each OL-containing well to lyse the cells.

Cell lysates were then

collected and stored at -80°C prior to extracting the RNA. The Qiagen RNeasy
Mini Kit was used to extract total RNA from each cell lysate using the optional
Qiagen RNase-Free DNase set for DNase digestion (Qiagen Inc, Valencia, CA).
Following the extraction, 1µl of each RNA sample was tested in an Agilent 2100
Bio-analyzer to determine the purity and quantity of RNA present. The remaining
sample was stored at -80°C.

Quantitative Real Time Polymerase Chain Reaction
Primers were ordered for selected Prdx4 and Mt3, was purchased from
SABiosciences (Frederick, MD; sequences are proprietary). Total RNA (10 ng/µl)
from OL cultures were subjected to qRT-PCR.

The RT reaction mixture

consisted of 3µl Oligo (dT) Primers, 10 µl cDNA Synthesis Master Mix (2X), 1 µl
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of Affinity Script RT/RNase Block enzyme mixture, and RNase-free H2O to a total
volume of 20 µl (Stratagene, La Jolla, CA). The reaction was incubated at 25°C
for 5 min to allow primer annealing, then incubated at 42°C for 45 min to allow
cDNA synthesis followed by 5 min incubation at 95°C to terminate the cDNA
synthesis reaction.
Complementary DNA from the RT reaction was added to a PCR reaction
mix consisting of 1 µl cDNA, 12.5 µl 2X Brilliant 490 SYBR Green QPCR Master
Mix (Stratagene), 2 µl primer, and nuclease-free PCR grade H2O to a total
volume of 25 µl. The samples were amplified using a BioRad ICycler (Bio-Rad
Laboratories, Hercules, CA) with the following protocol: heating to 95°C for 15
min followed by 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 55
°C, and 30 sec of elongation at 72°C. GADPH was used as a reference gene to
calculate the mean normalized expression.

Immunohistochemistry
For horseradish peroxidase detection, brain tissue sections/coverslips
were washed with PBS for 5 min and incubated in 3% hydrogen peroxide for 20
min. Sections were then washed 3 times in PBS, incubated for 1 hr in
permeabilization buffer (2% serum, 0.3% Triton X-100 and 0.3% 1M lysine in
PBS) and incubated overnight at 4̊C with primary antibody in antibody solution
(2% goat serum, 0.3% Triton X-100 in PBS). The following day, sections were
washed with PBS and incubated 1 hr at room temperature with secondary
antibody in antibody solution (2% serum, 0.3% Triton X-100 in PBS). Sections
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were then washed in PBS, incubated in Avidin-Biotin Complex (ABC; Vector
Laboratories Inc, Burlingame, CA) mixture for 1hr, washed again and visualized
using a DAB/peroxide solution (Vector Laboratories Inc). After 3 final washes,
sections were dried, dehydrated with increasing concentrations of EtOH (70%,
95%, 100%), cleared with xylene and cover-slipped with DPX mounting medium
(VWR International Ltd, Poole, England). Antibodies consisted of the following:
rabbit anti-phospho-Akt (Ser473) (Cell Signaling, Danvers, MA; 1:50), rabbit anticaspase 3 (Sigma-Aldrich, St. Louis, MO; 1:1000). Secondary detection was
achieved using biotinylated secondary antibodies (Vector Laboratories; 1:300)
corresponding to the respective species of primary antibodies.
For fluorescent labeling, tissue sections were subjected to the same
method used for peroxidase detection, prior to the secondary antibody
incubation, except that fluorescence samples were not incubated in hydrogen
peroxide. Double-label immunohistochemistry was achieved by co-incubating
the tissues with primary antibodies raised in two distinct species, followed by coincubation with secondary antibodies conjugated to distinct fluorophores.
Following secondary antibody incubation, sections were washed and coverslipped using VectaShield Hard Set with DAPI (Vector Laboratories). Antibodies
used for fluorescent detection consisted of the following:

mouse anti-RIP

(Millipore, Temecula, CA; 1:5000), rabbit anti-Phospho-Akt (Ser473) (Cell
Signaling, 1:50), rabbit anti-Caspase 3 (Sigma-Aldrich, 1:1000). Secondary
antibodies used were Alexa Fluor 488 and 594 (Molecular Probes, Eugene, OR;
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1:1000).

Negative controls were labeled in the absence of primary antibody

corresponding with respective secondary, as discussed previously.

Image Analyses
Following in vitro experiments, images were generated using a Zeiss
Axioskop2 microscope controlled by Openlab (Improvision Ltd, Lexington, MA)
software. Images were captured with a Zeiss Axiocam Color camera. The
ImageJ 1.410 program (National Institutes of Health, USA) was used to measure
total staining intensity and was expressed as ratios of total intensity vs. number
of cells, thus showing the relative area positive staining per cell.
For in vivo image analyses, brain sections from≥ 3 animals per group
were used.

Coronal brain sections encompassing the striatum (Bregma

coordinates +1.7 through -0.3) were taken from each animal. Images were
generated using a Zeiss Axioskop2 microscope controlled by Openlab software.
Images were captured with a Zeiss Axiocam Color camera. The ImageJ 1.410
program was used to measure relative total percent intensity ratios of ipsilateral
vs. contralateral hemispheres. Ratios were calculated for each animal due to
ipsilateral brain swelling caused by edema. The groups mean total intensity ratio
for each experimental treatment group was used for comparisons across
treatments. Total intensity analysis was conducted where treatment groups were
blinded.
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Statistical Analyses
Data from all experiments were quantified and analyzed using GraphPad
Prism 4.0 (GraphPad Software, La Jola, CA) software.

Main effects were

determined using one-way ANOVAs, followed by Dunnett’s post hoc tests to
detect significant differences across treatment groups. When two variables were
present, two-way ANOVAs were used followed by Bonferroni post hoc tests. A
“p” value < 0.05 was used as the threshold for significant differences.

Results
Determination of Efficacious LIF Concentration
To determine whether administration of LIF attenuates OL cell death as a
result of OGD, a concentration response was performed as depicted in figure 1.
LIF was added to media at concentrations ranging from 10ng/ml to 1000ng/ml.
OL cultures were subjected to 24 hrs OGD, after which cellular cytotoxicity was
determined by lactate dehydrogenase assay. A concentration of 200ng/ml LIF
was the most effective at rescuing OLs subjected to 24 hrs OGD (p<0.05, n= ≥3).

Akt Inhibition Blocked LIF Protection
Akt activation is critical for HUCB cell induced OL survival. Therefore we
blocked the Akt pathway to determine if this signal transduction pathway was
used by LIF to rescue OLs subjected to 24 hrs OGD. 10µM Akt inhibitor IV was
used to block Akt activation in OL cultures exposed to OGD. Increased OL cell
death occurred in cells exposed to OGD as compared to normoxic controls (n≥6,
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*p< 0.01), Again 200ng/ml LIF enhanced OLs survival ≥6,
(n #p<0.05) (Fig 1.).
This protection was completely blocked by Akt inhibition, where cytotoxicity levels
were similar to OGD only groups (p>0.05). Significant differences in LDH levels
were not observed among the treatment groups exposed to normoxic conditions
(p>0.05).

OGD Increased Akt Phosphorylation
Antibodies specific for Akt phosphorylated at serine 473 were used to
evaluate activation of the protein kinase in vitro following LIF treatment. Figure 3
shows that 24 of hrs OGD exposure increased Akt phosphorylation compared to
normoxica in OLs (n≥3, *p<0.05). LIF administration significantly increased Akt
phosphorylation relative to normoxic controls but not to OGD exposure alone
(n≥3, #p<0.01, p>0.05) respectively. The introduction of Akt inhibitor IV reduced
Akt phosphorylation to levels similar to those found in normoxic conditions (n=3
p>0.05). Akt phosphorylation was not different among treatment groups exposed
to normoxia (Figure 2 E, F, G, H, p>0.05).

LIF Increased OL Expression of Prdx4 and Mt3 in OL Cultures
Prdx4 and Mt3 are upregulated by HUCB cell treatment and are known to
reduce ROS accumulation by scavenging free radicals (Hozumi, Inuzuka et al.
1998; Hofmann, Hecht et al. 2002; Rowe, Leonardo et al. 2010). To determine if
Prdx4 and Mt3 expression are linked to LIF mediated oligoprotection, qRT-PCR
was performed to analyze Prdx4 and Mt3 gene expression in cultured OLs. LIF
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treatment increased Prdx4 and Mt3 mRNA when compared to OLs subjected to
OGD (Fig 4. n≥7, *p< 0.01). Prdx4 and Mt3 were increased 6.5±2.5 and 12±4.9
folds respectively. No significant differences were observed in normoxic groups.
GDPH was used as control in these experiments.

Akt Inhibitor IV Blocked LIF Induced Prdx4 Expression but
Increased Mt3 Expression
Akt inhibitor IV was employed to determine whether activation of Akt is
linked to expression of antioxidant genes. The addition of Akt inhibitor IV blocked
LIF induced Prdx4 expression. Differences in Prdx4 expression was not
observed in OGD only groups compared to OLs exposed to OGD coincubated
with Akt inhibitor IV + LIF and Akt inhibitor IV only groups (p>0.05, p>0.05)
respectively. Yet the addition of Akt inhibitor IV increased Mt3 expression as
compared to OGD alone (p<0.01). Mt3 expression was increased in ODG + LIF +
Akt inhibitor and OGD + Akt inhibitor groups 39.6±8.8 and 28±4.1 folds
respectively. This finding was consistent with previous reports in which inhibition
of Akt and Akt effectors increased Mt3 expression in human hepatocellular
carcinomas (Datta, Majumder et al. 2007).

LIF Reduced SOD Activity in OL Cultures
To determine oxidative stress, SOD activity was measured. We showed
that LIF treatment significantly reduced SOD activity in media compared to OGD
alone (p<0.05). Furthermore, addition of Akt inhibitor IV increased SOD activity to
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levels similar to those found in OGD, where OGD was not different from OGD +
LIF + Akt inhibitor and OGD+ Akt inhibitor (p>0.05, p>0.05) respectively.

LIF Neutralizing Antibody Did Not Block HUCB Cell Effect
To evaluate LIF in HUCB cell mediated OL protection, a LIF neutralizing
antibody was used to block the effects of LIF. Exposure to 24 hrs OGD increased
OL cell death as compared to normoxic control (n ≥ 6, *p < 0.01), whereas HUCB
cell co-incubation reduced OGD induced cell death ≥(n6, #p < 0.05). The
addition of 10ug/ml LIF neutralizing antibody with HUCB cell treatment had no
effect. Additionally, LIF neutralizing antibody did not affect HUCB cell mediated
reduction of SOD activity as shown in figure 7B. Treatment with HUCB cells and
HUCB cells + antiLIF significantly reduced SOD activity in OL culture media (*p <
0.05).Therefore the addition of LIF neutralizing antibody did not block HUCB cell
induced oligoprotection.

GCSF Rescued OLs from 24 hrs OGD
Because LIF neutralizing antibody did not block HUCB cell effects, we
evaluated the ability of an additional soluble factor to attenuate OGD induced OL
dysfunction. A concentration response was performed. GCSF was added to
media ranging from 10ng/ml to 1000ng/ml, after which OLs were exposed to 24
hr OGD. A concentration of 200ng/ml was discovered as the most effective
GCSF concentration at rescuing OLs subjected to 24 hrs OGD (p<0.05, n ≥4).
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Akt Inhibitor IV Blocked GCSF Mediated Effects
We blocked the PI3/Akt pathway using 10µM Akt inhibitor IV in OL
cultures treated with GCSF and exposed to OGD. OGD exposure resulted in
increased OL cell death as compared to normoxic controls (n≥6, *p< 0.01), where
200ng/ml GCSF coincubation increased survival of OLs (n≥6, #p<0.05) (Fig 1.).
GCSF mediated protection was blocked by Akt inhibition, where cytotoxicity
levels were similar to OGD only groups (p>0.05). Furthermore, combining LIF
and GCSF treatment did not increase cell survival relative to LIF treatment alone
but significant from OGD (p>0.05, p<0.05) respectively figure 9B. Significant
differences were not observed in OL cell death among the treatment groups
exposed to normoxic conditions (p>0.05).

Discussion
We showed that the pleiotropic cytokine LIF attenuated OGD induced OL
cell death. LIF activity was transduced through Akt activation and upregulated
antioxidant gene expression leading to reduction of ROS production thus
increasing cellular survival of primary OLs.
OGD is a commonly used in vitro model of stroke. Previously, HUCB cells
has been shown to protect OLs from cell death attributed to OGD by secreting
soluble factors (Rowe, Leonardo et al. 2010). LIF and GCSF are two soluble
factors expressed and secreted by HUCB cells (Neuhoff, Moers et al. 2007). LIF
activity is modulated through surface receptors, specifically LIF binds LIFR at low
affinity, but this affinity is increased once LIF is bound to gp130 (Gearing,
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VandenBos et al. 1992; Kurek 2000). Following LIF binding, LIFR and gp130
dimerizes to activate the gp130 intracellular signaling cascade relaying the signal
to the janus kinase signal transducer and activator for transcription (JAK/STAT),
Ras mitogen activated protein (MAPK) and the PI3/Akt pathway (Oh, Fujio et al.
1998; Tanaka, Hijioka et al. 2004; Hall, Karplus et al. 2009).
In the present study, LIF administration attenuated OGD induced OL cell
death. The optimal concentration of 200ng/ml LIF reduced cellular cytotoxicity in
OLs exposed to 24 hrs OGD. This result is in agreement with previous studies in
which LIF rescued OLs in disease states such as spinal cord and EAE injury
(Kerr and Patterson 2005; Azari, Profyris et al. 2006; Butzkueven, Emery et al.
2006) .
HUCB cells mediated oligoprotection through the activation of the PI3/Akt
survival pathway (See Chapter 3). Additionally, LIF administration activated the
Akt survival pathway and blocked caspase 3 cleavage post spinal cord injury
(Azari, Profyris et al. 2006). Our goal was to identify soluble factors that emulate
the action of HUCB cells. Thus, a specific Akt inhibitor was used to assess the
role of Akt in LIF mediated OL protection. We report that the addition of Akt
inhibitor IV abolished LIF protection in OL cultures exposed to OGD. No
difference was observed in assessing Akt phosphorylation in OLs exposed to 24
hrs OGD compared to cells treated with LIF. Where OGD alone increased
phosphorylation of Akt in OLs subjected to OGD. Previous reports showed
increased Akt activation following OGD, additionally Akt is rapidly phosphorylated
at serine 473 in various models of ischemia. These results suggest the activation
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of intrinsic cellular survival mechanisms, where Akt activation enhance cellular
survival and halt apoptosis. (Zhao, Sapolsky et al. 2006).
OGD

induces

ROS

production

and

PI3/Akt

activation

attenuate

mitochondrial dysfunction, therefore we investigated the role of antioxidant gene
expression in LIF protection (Zhao, Sapolsky et al. 2006). The high oxygen
consumption and availability of peroxidizable lipids renders the brain susceptible
to oxidative stress post stroke. Superoxide is the primary ROS from which other
ROS are generated (Allen and Bayraktutan 2009). In ischemia, ROS/antioxidants
imbalances result in protein denaturation, lipid peroxidation, DNA damage and
cell death. Furthermore, oxidative stress is a major cause of OL cell death
resulting from stroke (Dewar, Underhill et al. 2003). This susceptibility has been
linked to OLs high metabolic rate, high energy consumption, low antioxidant and
high Iron content (McTigue and Tripathi 2008). OL’s low antioxidant content
leaves cells unable to cope with the accumulation of ROS/RNS (Juurlink 1997;
Juurlink, Thorburne et al. 1998). Iron is an important myelin cofactor that is highly
reactive and conducive to the generation of ROS/RNS to free radical formation
and lipid peroxidation following stroke (Braughler, Duncan et al. 1986; Connor
and Menzies 1996; McTigue and Tripathi 2008; Allen and Bayraktutan 2009).
Therefore the regulation of antioxidants is a potential target in OL protection.
Previously we showed that HUCB cell rescued OL via regulation of the
antioxidants Prdx4 and Mt3 (Rowe, Leonardo et al. 2010).
Prdx4 and Mt3 are members of antioxidant families that act as free radical
scavengers (Hozumi, Inuzuka et al. 1998; Hofmann, Hecht et al. 2002). Prdx4
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possess peroxidase activity, detoxifying a range of free radical-forming organic
hydroperoxides (Hofmann, Hecht et al. 2002). Mt3 is involved in the detoxification
of heavy metals such as mercury (Hozumi, Inuzuka et al. 1998; Uchida, Gomi et
al. 2002; Hwang, Kim et al. 2008). Furthermore Prdx family undergo structural
changes to engage in chaperone activity in response to excessive oxidation
(Jang, Lee et al. 2004). This chaperone activity prevents free radical-induced
aggregation of cytosolic proteins (Jang, Lee et al. 2004; Kang, Rhee et al. 2005).
LIF treatment increased Mt3 and Prdx4 expression in cultured OLs
exposed to OGD. These reports support previous findings where LIF inhibited the
production of pro inflammatory mediators including TNFα and ROS by
macrophages (Hendriks, Slaets et al. 2008). Under biological stress, ROS are
generated where antioxidant such as SOD are upregulated to combat oxidative
stress. If ROS are generated to toxic levels, cell death will result (Allen and
Bayraktutan 2009). Upon further investigation using a superoxide activity, we
confirmed that LIF treatment reduced ROS generation in media from OL cultures
exposed to OGD. In these experiments, SOD activity was elevated in cultures
exposed to OGD. This increase in SOD could be a result of cellular response to
OGD induced superoxide production. These results suggest that LIF treatment
reduced ROS production, therefore lowering SOD activity. These results also
explained the increase in Mt3 expression as a result of Akt inhibition. Inhibition
of Akt has been previously shown to increase Mt3, but a rationale has not been
developed or tested (Datta, Majumder et al. 2007). Thus we postulate that Akt
inhibitor IV blocked the PI3/Akt survival pathway resulting in the accumulation of
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ROS as demonstrated by the SOD activity assay, where increased SOD activity
was observed with the addition of Akt inhibitor. This accumulation of ROS could
lead a cellular response increasing antioxidants such as Mt3, thus an increase in
Mt3 gene expression was observed.
These results are in opposition to the study done by Slaets et. al where
LIF rescued OLs from proinflammatory cytokines such as TNFα and IFNγ
induced apoptosis, but not oxidative stress. This conflict was resolved by
increasing LIF therapeutic concentration. In the previous study by Slaets et. al,
15ng/ml LIF was used as treatment. At identical LIF concentrations, LIF did not
rescue OLs subjected to OGD as shown in figure 1, but at an increased
concentration of 200ng/ml cellular protection was observed.
As previously mentioned, HUCB cells secrete a number soluble factor. To
assess the potency of LIF as compared to other soluble factors secreted by
HUCB cells, we used a LIF neutralizing antibody to block the effects of LIF. With
the neutralizing antibody, HUCB cells protection was maintained as previously
reported by Rowe Et. Al and SOD levels were not affected. These results show
that other soluble factors secreted by HUCB cells such as GCSF are also
important
GCSF promotes proliferation, differentiation and survival (Avalos 1996).
GCSF alike LIF and other HUCB cell secreted factors activate the Akt pathway
(Hunter and Avalos 1998; Neuhoff, Moers et al. 2007; Slaets, Dumont et al.
2008). We showed that GCSF protected OL from OGD induced death, the
presence of Akt inhibitor IV blocked this effect. These results point to the role of
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each secreted factor of HUCB cell, where these factors work in synergy to
activate the PI3/Akt pathway to increase cellular survival. In the absence of LIF
activity, as shown with the inclusion of a LIF neutralizing antibody, other soluble
factors compensated. Interestingly, the combination treatment of LIF and GCSF
did not decrease cellular cytotoxicity compared to LIF treatment alone. Therefore
it can now be stated that LIF is not solely responsible for HUCB cell protective
effects.
Previous studies have highlighted LIF protective effects in disease states
including spinal cord injury and EAE (Kerr and Patterson 2005; Azari, Profyris et
al. 2006; Butzkueven, Emery et al. 2006) . Furthermore, LIF expression is
upregulated in vitro in cells exposed to OGD, and is rapidly expressed in the
infarct boundary post stroke (Slevin, Krupinski et al. 2008). This upregulation in
disease states appears to have a protective effect. Here we show that LIF
rescued OLs subjected to OGD via activation of the Akt pathway. Furthermore,
we established that LIF increased OL antioxidant production in an oxygen
deprived environment. Future studies investigating LIF activity in vivo following
stroke will be instrumental in establishing more detailed mechanisms of LIF on
OLs and the cerebral white matter following ischemia.
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Figure 1. LIF Attenuate Stroke Induce OL Dysfunction. LIF was co-incubated
with OL at concentrations of 10ng/ml 50, 200 and a final concentration of
1000ng/ml. OL cultures were subjected to 24 hrs OGD. OGD increased cell
death an appreciable amount, and cytotoxic effect was slightly increased with
10ng and 50ng LIF treatment. 200ng/ml LIF rescued OLs subjected to 24 hrs
OGD compared to OGD alone (p<0.05, n= ≥ 3), where 10, 50 and 1000ng/ml
was not different from OGD controls (p>0.05). Beyond 200ng to 1000ng/ml, LIF
was not protective. Here represents a biphasic effect of LIF.
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Figure 2. Akt Inhibition Negates the Protective Effects of LIF on Cultured
OLs. An increase in OL cell death was detected in cultures subjected to 24 hr
OGD compared to normoxic controls (n
≥ 6, *p < 0.01), demonstrating OGD induced cellular injury. OL cultures subjected to OGD were rescued by coincubation with 200ng/ml LIF (n ≥ 6, #p < 0.05), cell death was reduced back to
levels present in normoxic controls (p>0.05). Addition of Akt Inhibitor IV
eliminated LIF oligoprotective effects in cultures exposed to 24hr OGD (p > 0.05).
Additionally, there was no effect of treatment on OLs exposed to normoxic
conditions.
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Figure 3. OGD Increased Akt Phosphorylation in OLs Subjected to 24 hrs
OGD. Immunohistochemistry was performed using an antibody generated
against Akt phosphorylated at serine 473. Micrographs show immunoreactivity in
OLs exposed to OGD (A-D) or normoxia (E-H). Treatment groups were vehicle
(A, E), LIF (B, F), Akt Inhibitor IV (C, G) or LIF + Akt Inhibitor IV (D, H).
Quantification (I) revealed increased Akt phosphorylation in OLs exposed to
OGD relative to normoxic controls (n ≥3, *p < 0.05). Addition of LIF resulted in an
additional increase in phosphorylation during OGD relative to vehicle-treated
normoxic controls but not OGD (n ≥ 3, #p < 0.001, p > 0.05) respectively. Akt
Inhibitor IV reduced phosphorylation during OGD when added in the presence or
absence of LIF, such that immunoreactivity was not different from normoxic
controls. Scale bars = 50 μm.
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Figure 4. LIF Increased OL Expression of Prdx4 and Mt3 in OL Cultures.
qRT-PCR was performed to quantify mRNA expression of the antioxidant
enzyme Prdx4 and Mt3. OLs were subjected to OGD or normoxia and treated
with LIF. LIF increased Prdx4 (6.5±2.5 folds (A) and Mt3 (12±4.9) folds (B) gene
transcript compared to vehicle-treated controls (n ≥ 7, *p < 0.01,). No differences
were observed in normoxic controls.
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Figure 5. Akt Inhibitor IV Suppresses LIF Induced Prdx4 Expression but
Increased Mt3 expression. OLs were subjected to OGD and treated with LIF in
the presence of Akt Inhibitor IV. Akt Inhibitor IV blocked LIF induced Prdx4
expression across all treatment groups as compared to OGD (p> 0.05). Akt
inhibitor IV increased MT3 expression compared to vehicle-treated controls (n ≥
7, *p < 0.01). Mt3 expression was increased in ODG + LIF + Akt inhibitor and
OGD + Akt inhibitor groups 39.6±8.8 and 28±4.1 folds respectively.
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Figure 6. LIF Reduced SOD Activity in Primary OL Cultures. OGD causes
SOD activity in OL cultures subjected to 24 hrs OGD. LIF treatment significantly
reduced SOD activity compared to OGD controls (n ≥ 5, *p < 0.05). The presence
of Akt inhibitor IV in groups OGD + LIF + Akt inhibitor and OGD + Akt inhibitor
increased SOD activity where no differences in SOD activity was observed
compared to vehicle-treated controls (p> 0.05).
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Figure 7. LIF Neutralizing Antibody Did not Block HUCB Cell Effect. Media
from OL cultures subjected to OGD-only contained elevated levels of LDH
compared to media from normoxic controls, demonstrating OGD-induced cellular
injury (n ≥ 6, *p < 0.01). OL cultures subjected to OGD were rescued by c oincubation with HUCB cells (n ≥ 6, #p < 0.05). The addition o f 10ug/ml LIF
neutralizing antibody with HUCB cell treatment maintained HUCB cell protection
compared to OGD alone, and not different from HUCB cell treatment (p < 0.05,
p>0.05) respectively. In figure (B), neutralizing antibody did change SOD levels
associated with HUCB cell treatment. HUCB cells and HUCB cells + LIF reduced
Sod activity (* p < 0.05).
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Figure 8. GCSF Rescued OLs from 24 hrs OGD. In our trial, 10, 50, 200 and
1000ng/ml GCSF was used to assess the drug efficacy. Here, 200ng/ml GCSF
rescued OLs subjected to 24 hrs OGD, when compared to OGD only groups
(p<0.05, n ≥4).
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Figure 9. Akt Inhibitor IV Blocked GCSF Mediated Effects. 10µM Akt inhibitor
IV was used to block Akt phosphorylation in OL cultures exposed to OGD. 24 hr
OGD exposure resulted in increased OL cell death as compared to normoxic
controls (n≥6 , *p< 0.01). 200ng/ml GCSF coincubation rescued OGD exposed
OLs (n≥6, #p<0.05) (Fig 1.). GCSF mediated protection was blocked by Akt
inhibition, where cytotoxicity levels were similar to OGD only groups (p>0.05). As
depicted in figure 9B, combining 200ng LIF and 200ng GCSF treatment did not
increase cell survival relative to LIF treatment alone but significant from OGD
(p>0.05,* p<0.05). These results demonstrate that LIF is not the only HUCB cell
secreted factor that rescues OL subjected to 24hr OGD. Significant differences
were not observed in OL cell death among the treatment groups exposed to
normoxic conditions (p>0.05).
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Overview
The serine protease t-PA is currently the only Food and Drug
Administration (FDA) approved treatment for acute ischemia (Pan, Yu et al.
2008). t-PA restores blood flow to ischemic areas by enzymatically dissolving
clots by catalyzing the conversion of plasminogen to plasmin, but this treatment
does not possess neuroprotective activity. Furthermore, t-PA treatment must be
administered within 4 hours of stroke onset to benefit stroke patients (Hacke,
Donnan et al. 2004). As a result, only 3-5% of stroke patients are able to use tPA (Marler and Goldstein 2003; Association 2008). Additionally, t-PA
administration beyond this limited therapeutic time window is ineffective and
could prove detrimental. The main concern of t-PA use outside 4 hrs of stroke
onset is the increased risk of hemorrhages that accompanies delayed treatment
(Hacke, Donnan et al. 2004). Thus, new stroke therapies are needed to extend
the therapeutic time window providing treatment for a larger population of those
who has suffered an ischemic stroke.
Cell based therapy represents a growing area of viable treatments for an
array of neurological diseases including stroke. Previously, cell based therapy
was reserved for life-threatening injuries mainly because of the associated graftversus-host disease and related infections. Such diseases are a direct result of
immune suppressive techniques such as chemotherapy and irradiation,
techniques necessary to reduce host rejection of foreign engrafted cells
(Sanberg, Willing et al. 2005). The use of HUCB cells circumvents the
aforementioned immunogenic

issues

partly
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because

they possess low

immunogenicity (Wang, Yang et al. 2009). HUCB cells also have major
histocompatibility complex I (MHC I) but not MHC II, CD40, CD80 or CD86 costimulatory molecule, these proteins are known to be expressed by antigen
presenting

cells

and

tissues

(Wang,

Yang

et

al.

2009).

The

low

immunomodulatory effects of HUCB cells give it an advantage over other cell
based therapies as a potential therapeutic.
HUCB cells were first shown to improve behavioral recovery when
treatment was given systemically 24 hrs following stroke. In this study, implanted
cells migrated to the infarct boundary and localized in the cortex, subcortex and
the striatum where significantly less transplanted cells were found in the
contralateral hemisphere (Chen, Sanberg et al. 2001). To extend the therapeutic
time window, HUCB cell treatment was assessed 48 hrs post stroke. Intravenous
administration of HUCB cell (1x106) 48 hrs post middle cerebral artery occlusion
(MCAO) resulted in reduced infarct volume, and behavioral recovery compared
to stroked animals (Vendrame, Cassady et al. 2004; Newman, Willing et al. 2005;
Hall, Guyer et al. 2009). The cytokines MIP-1α and MCP-1 were found to
modulate HUCB cell movement to the site of injury. Specifically, MCP-1 and
Mip1α receptors are constitutively expressed by HUCB cells, whereas these
proteins are significantly upregulated in the ischemic brain (Jiang, Newman et al.
2008). In vitro, HUCB cells rescued oligodendrocytes (OL)s subjected to 2 hrs
OGD as demonstrated by reduced OGD induced caspase activation.
Furthermore striatal white matter tracts were preserved in animals subjected to
MCAO that received HUCB cell treatment 48 hrs post-surgery (Hall, Guyer et al.
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2009). These experiments highlighted the potential of HUCB cells to protect not
only the gray matter but also the white matter following an ischemic insult.
The narrow focus on gray matter preservation following ischemia has
resulted in few therapies showing success in human trials when moved from
rodent models. In rodents, the gray matter occupies 90% of the brain volume
while the white matter occupies the other 10%. In large animals including
humans, the white matter and gray matter each occupy 50% of total brain volume
(Miller, Alston et al. 1980). OLs of the white matter produce myelin to support
axonal structural integrity for impulse propagation and integration (Baumann and
Pham-Dinh 2001). Thus, white matter protection is not only necessary but
essential to the maintenance of communication between brain areas (Arai and Lo
2009).

HUCB Cells Rescued OLs
The protective effects of HUCB cells on the gray and white matter
indicated that these cells are an ideal therapeutic candidate for stroke. The first
important finding of the studies reported herein is that HUCB cells rescued OL
subjected to 24 hrs OGD. When 1x106 HUCB cells were co-incubated with 3x105
primary OLs then subjected 24 hrs OGD, OL cytotoxicity was significantly
reduced as tested by Lactate Dehydrogenase assay (LDH). LDH is restricted to
the cytoplasmic space, therefore its presence in cellular media denotes damaged
cells. HUCB cells possess major therapeutic potential because unlike other cell
based therapies, HUCB cells are readily available and elicit very low
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immunogenic response. Therefore HUCB cells are easily administered without
the concerns of painful retrieval as with bone marrow cells or the potential to elicit
a graft versus host response. There are concerns in regards to cell based
therapy. One such concern is the ethical use of cell based therapy, these
apprehensions centers on the issue of morality. But also, there is a concern of
how to standardize cell based therapy. With such concerns, limitation maybe
placed on HUCB cells as an effective therapy. Therefore it is important to discern
the active components of HUCB cell mononuclear fraction that possess neural
protective properties.
The use of transwell inserts in the current studies identified that HUCB
cells secrete soluble factors that mediate these protective effects. The use of 0.2
µm transwell inserts allowed only soluble factors secreted by HUCB cells to
interact with primary OLs. Cytokines, chemokines, interleukins, metalloproteinase
inhibitors and growth factors are secreted by HUCB cells (Newman, Willing et al.
2006; Neuhoff, Moers et al. 2007). These factors secreted by HUCB cells are
known to alter gene expression (Rowe, Leonardo et al. 2010). Many gene
changes were observed by microarray and confirmed by qRT-PCR. HUCB cells
increased Prdx4, Mog, Stmn2, Mt3, Tspan2, Vcan, and Insig1 gene expression in
OLs subjected to 24 hrs OGD.
From these experiments, HUCB cells protected OLs subjected to OGD by
altering gene expression. But the question remains, do gene changes in vitro
result in altered protein expression in OLs, and what are the consequences of
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these changes? We look to answer these questions in the in vivo experiments
that follow.

HUCB Cells Enhance Survival Protein Expression
HUCB cells given intravenously post MCAO migrate to the infarct and
reduce infarct volume and behavioral deficits (Chen, Sanberg et al. 2001;
Vendrame, Cassady et al. 2004). As pointed out in chapter 2, when HUCB cells
were given intravenously 48 hrs post MCAO, in brain tissues analyzed, only a
fraction of the protein products of genes identified by microarray analysis
changed. HUCB cell treatment increased Prdx4, Mt4, Uhmk1, Mog, and Insig1
protein expression in OLs residing in the external capsule of the white matter
tract adjacent to the infarct. One possible explanation is that protein translation is
not entirely dependent on changes in gene transcription. Double staining of brain
sections identified that OLs were indeed expressing each individual protein.
Prdx4 and Mt3 represent two family of antioxidant enzymes actively
involved in cellular detoxification. Prdx4 exerts protective effects through
peroxidase

activity,

mainly

detoxifying

free

radical-forming

organic

hydroperoxides such as hydrogen peroxide and peroxynitrite (Hofmann, Hecht et
al. 2002). Prdx4 interactions with substrates convert these substrates to water
(Zito, Melo et al. ; Hall, Karplus et al. 2009). Furthermore, Prdx4 regulates the
thromboxane A2 receptor, thromboxane A2 is upregulated by oxidative stress
and contributes to oxidative injury upon activation (Valentin, Field et al. 2004).
The overexpression of Prdx4 inhibits thromboxane A2 expression (Giguere,
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Turcotte et al. 2007).

In addition, the Prdx family has also been shown to

undergo structural changes to engage in chaperone activity in response to
excessive oxidation, a function that prevents free radical-induced aggregation of
cytosolic proteins (Jang, Lee et al. 2004; Kang, Rhee et al. 2005). Similarly to
Prdx4, the antioxidant Mt3 exerts its effects through metal detoxification and free
radical scavenging activity (Hozumi, Inuzuka et al. 1998; Uchida, Gomi et al.
2002; Hwang, Kim et al. 2008). Mt3 detoxifies cells by reducing heavy metals
such as mercury and cadmium (Hidalgo, Aschner et al. 2001). Furthermore, Mt3
activates the PI3K/Akt signaling pathway reducing H2O2 induced caspase
activation and cell death (Kim, Hwang et al. 2009). In the same study, Mt3
treatment resulted in the upregulation of heme oxygenase 1, where inhibition of
Akt abolished Mt3 effect (Hwang, Kim et al. 2008).
HUCB cell treatment also altered the expression of proteins involved in
microtubule regulation, cell proliferation and cholesterol biosynthesis. MOG is a
late stage myelinating protein that has been shown to inhibit microtubule
polymerization (Johns and Bernard 1999). The protein Uhmk1 induces
proliferation and cell cycle progression through the phosphorylation of p27kip1
(Nakamura, Okinaka et al. 2008). Previous findings showed that mature OLs
retain the ability to proliferate following injury. This result was obtained following
white matter damage where new cells were generated. This study postulated the
dedifferentiation and proliferation of OLs in the white matter (Wood and Bunge
1991). Additionally, Insig1 as previously mentioned was upregulated in the white
matter tract following HUCB cell administration post stroke. Insig1 is degraded
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when cholesterol is depleted within a cell (Gong, Lee et al. 2006), Hypoxia
increases Insig1 expression through a mechanism mediated by hypoxia inducible
factor 1α (Nguyen, McDonald et al. 2007). Thus, the elevations in Insig1 likely
reflect HUCB cell induction of cholesterol biosynthesis aimed at remyelination or
restoration of the cell membrane. This result is not surprising with the increased
proportion of O4 positive cells following HUC B cell treatment.
The results obtained in this study demonstrated that HUCB cells increased
OL antioxidant enzyme expression of Prdx4 and Mt3 post MCAO. Myelin was
also maintained in the peri-infarct region following the increased expression of
proteins such as Uhmk1, Mog and Insig1. This maintenance of myelin was
evident where a significant increase in O4 positive cells were detected in the
external capsule of HUCB cell treated groups; O4 is a specific OL/myelin marker
that is expressed by both immature and mature cells.

Mechanism by Which HUCB Cells Exert Beneficial Effects
Both in vitro and in vivo findings led us to investigate the pathway utilized
by HUCB cells to induce protein expression and OL survival. Upon intravenous
administration, HUCB cells enter the circulatory system and the brain as the
blood brain barrier is open at this time point post stroke. HUCB cells migrate to
the infarct boundary where soluble factors are secreted (Chen, Sanberg et al.
2001; Vendrame, Cassady et al. 2004; Neuhoff, Moers et al. 2007; Jiang,
Newman et al. 2008). These secreted factors include growth factors,
metalloproteinase inhibitors, interleukins, cytokines and chemokines (Neuhoff,
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Moers

et

al.

2007).

The

aforementioned

interleukins,

growth

factors,

metalloproteinase inhibitors and cytokines are known for specific yet merging
functions. These functions include angiogenic, chemotactic, neuroprotective and
anti-inflammatory actions which contribute to the therapeutic effect of HUCB
cells. Eleven factors secreted by HUCB cells have been shown to induce Akt
activation, these soluble factors include GDNF, GCSF, BDNF, LIF, IL-1β, IL-6,
IGF1, VEGF and TIMP-1 (Kulik, Klippel et al. 1997; Dolcet, Egea et al. 1999; Jin,
Mao et al. 2000; Jin, Omori et al. 2003; Lee, Yoo et al. 2003; Lentzsch,
Chatterjee et al. 2004; Wegiel, Bjartell et al. 2008). In addition to Akt activation,
factors such as VEGF, BDNF, PDGF-B, LIF and GCSF are known for their
proliferative and anti-inflammatory effects (Kulik, Klippel et al. 1997; Jin, Mao et
al. 2000; Newman, Willing et al. 2006; Neuhoff, Moers et al. 2007).
Akt is quickly phosphorylated following ischemic injury. This rapid
activation of Akt is thought to be an intrinsic survival mechanism (Zhao, Sapolsky
et al. 2006). When phosphorylated at serine 473, Akt transduces cellular survival
signals by inhibiting apoptotic cascades and promoting activation of cell survival
effectors and pathways. (Kennedy, Wagner et al. 1997; Zhao, Sapolsky et al.
2006). Activated Akt phosphorylate BAD, pro caspase 9 Forkhead and nuclear
factor kappa B (NFκB) in a manner inhibiting apoptosis. Specifically, Akt inhibits
the activation of BAD and Forkhead family of transcription factor by direct
phosphorylation thus preventing the upregulation of pro apoptotic molecules such
as Fas ligand (FasL) and BCL-2 interacting mediator of cell death (Bim).
(Hanada, Feng et al. 2004; Zhao, Sapolsky et al. 2006). In contrast, inactivated

181

Akt results in mitochondrial dysfunction leading to cytochrome c release, caspase
9 and poly (ADP-ribose) polymerase (PARP) cleavage (Nicholson, Ali et al. 1995;
Le Rhun, Kirkland et al. 1998; Datta, Brunet et al. 1999; Yu, Andrabi et al. 2006;
Zhao, Sapolsky et al. 2006). These substrates activates initiator caspase (2, 8, 9,
10) followed by the activation of execution caspases (3, 6, 7) resulting in
apoptosis (Zhao, Sapolsky et al. 2006). Once activated, caspase 3 is extensively
involved in the apoptotic cascade, actively cleaving a number of substrates. Two
such substrates are caspase 6 and 7. Upon cleavage, these substrates execute
programmed cell death via the disruption of the electron transport chain, causing
DNA fragmenting and cell shrinkage (Porter and Janicke 1999; Ricci, Gottlieb et
al. 2003).
Growth factors effectively bind to respective receptors activating tyrosine
kinases leading to activation of the PI3/Akt pathway. In vitro, HUCB cells rescued
OL subjected to 2 hrs OGD via caspase regulation (Hall, Guyer et al. 2009).
Furthermore, it was previously shown that HUCB cell protected neurons from
glutamate induced apoptosis via activation of the PI3/Akt pathway. Thus to
investigate the mechanism of HUCB cell mediated protection, the PI3/Akt
pathway represented an ideal target (Dasari, Veeravalli et al. 2008).
In the studies described herein, the addition of Akt inhibitor IV blocked
HUCB cell mediated protection of OLs subjected to 24 hrs OGD. Furthermore, in
groups treated with Akt inhibitor, HUCB cell induced Prdx4 gene expression was
blocked. In OL cultures treated with HUCB cells, Akt phosphorylation was
significantly increased, but was significantly reduced in Akt inhibitor treatment

182

groups. These results demonstrated that protection of OLs by HUCB cells is
transduced through Akt activation. Additionally, in vivo application of HUCB cells
48 hrs post MCAO increased phosphorylated Akt when compared to untreated
groups. Thus, it was not a surprise to find that activated caspase 3 was robust in
animals subjected to MCAO, but treatment with HUCB cells blocked caspase
activation in the external capsule.
Results from these experiments suggest that Akt plays a major role in
HUCB cell mediated oligoprotection. The soluble factors secreted by HUCB cells
activated Akt leading to the transduction of cellular survival signals. The concerns
questioning the standardization of cell base therapy is unavoidable, thus
alternatives to cell based therapy such as HUCB cells are needed. An ideal
group of therapeutic targets are HUCB cell secreted factors that mimicked HUCB
cellular protective effects. The following experiments examined two such soluble
factors.

LIF Replaced HUCB Cell Treatment.
Next we investigated whether a soluble factor secreted by HUCB cell
would elicit similar effects. LIF is a 180 amino acid single 4-α-helix pleiotropic
glycoprotein that interacts with a surface receptor and the gp130 receptor chain
(Kurek 2000). LIF activates Jak/Stat, Ras, MAPK and the PI3/Akt pathways
(Stahl, Boulton et al. 1994; Stahl, Farruggella et al. 1995; Oh, Fujio et al. 1998).
In unpublished data in collaboration with faculty, LIF is upregulated in HUCB cells
compared to peripheral blood (Dr Willing’s unpublished data). Additionally, of the
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factors secreted by HUCB cells LIF was chosen because of the lack of research
on the effects of this cytokine in stroke. But also comprehensive research had
been done assessing LIF action at rescuing OLs in different disease states. LIF
rescued OLs and reduced demyelination following spinal cord injury through
STAT 3 and PI3/Akt survival pathway activation (Metcalf and Gearing 1989;
Azari, Profyris et al. 2006). LIF rescued mature cultured OLs from the pro
inflammatory cytokines interferon γ and tumor necrosis factor α, through the
activation of both JAK/STAT and PI3/Akt pathway (Slaets, Dumont et al. 2008).
These studies showed the effects of LIF on OLs but also pointed out LIF ability to
activate the PI3/Akt pathway.
First, a concentration response curve was developed to find the most
effective concentration of LIF that would attenuate OL cell death induced by 24
hrs OGD. As shown in chapter 3, LIF concentration of 200ng/ml rescued OL
subjected to 24 hrs OGD. The data represents a small concentration dependent
window in which LIF is effective. This result could be attributed to the pleiotropic
effects of LIF at varying concentrations.
LIF treatment increased Mt3 and Prdx4 gene expression as well as Akt
activation in OLs exposed to OGD. As discovered with HUCB cell treatment, the
inclusion of Akt inhibitor IV blocked LIF mediated OL protection. Furthermore the
inclusion of Akt inhibitor IV blocked LIF induced Prdx4 gene expression but
significantly increased Mt3. Therefore we postulate that Akt inhibitor blocked
cellular protection thereby increasing cellular reactive oxygen species (ROS)
production. As a response to this increased ROS, Mt3 is upregulated as part of
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an intrinsic cellular protection mechanism. To test this hypothesis, a superoxide
dismutase (SOD) kit was used. In the presence of ROS specifically superoxide
production, cells react by increasing the production of SOD to eliminate free
radicals. Therefore, in a ROS rich environment, we expected increased SOD
activity as compared to treatment in which antioxidant production is increased as
a result of treatment. In our experiments, SOD activity in OL media was similar in
OGD and Akt inhibitor groups. In comparison, SOD activity was significantly
reduced in LIF treatment groups. Therefore as expected, LIF treatment reduced
ROS production, which is increased by the inclusion of Akt inhibitor. These
results confirm the hypothesis that LIF treatment increased Akt activation and
antioxidant activity leading to cellular survival. In contrast the inhibition of Akt
phosphorylation increased cellular ROS production, thus increasing SOD activity
and Mt3 expression to combat ROS accumulation.

LIF Neutralizing Antibody Did Not Block HUCB Cell Effect
To assess whether LIF is a major contributing soluble factor in the cocktail
secreted by HUCB cells in ischemic protection, LIF was blocked using a 10 µg/ml
neutralizing antibody. This antibody concentration was used particularly because
it was above was what necessary to block the 200ng LIF used to protect OLs
exposed to OGD. In these experiments we showed that LIF neutralizing antibody
did not block HUCB cell effect in vitro. SOD activity was not affected by the
inclusion of LIF neutralizing antibody in groups treated with HUCB cells.
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GCSF Protected OLs Exposed to OGD
To elaborate on this effect, we also evaluated granulocyte colonystimulating factor (GCSF), another factor secreted by HUCB cells. GCSF is a
pleiotropic factor shown to promote proliferation differentiation and survival
(Avalos 1996). GCSF like LIF and the multitude of HUCB cell secreted factors
activate the PI3/Akt pathway (Hunter and Avalos 1998; Neuhoff, Moers et al.
2007; Slaets, Dumont et al. 2008). In these experiments we showed that GCSF
protected OLs subjected to OGD specifically at a concentration of 200ng/ml. In
previous reports GCSF has been shown to be neuroprotective following ischemia
(Solaroglu, Cahill et al. 2006). Both GCSF and GCSF receptors are upregulated
in neurons exposed to hypoxia, suggesting an autocrine response to neuronal
injury. Furthermore, GCSF exerts its protective actions through neurogenesis,
the inhibition of apoptosis and by blocking the inflammatory response following
an insult (Solaroglu, Jadhav et al. 2007). GCSF modulation of inflammatory
mediators was evident where following MCAO, GCSF administration down
regulated NFκB and inducible nitric oxide synthase (iNOS) in the infarct area
(Sehara, Hayashi et al. 2007). Additionally, GCSF was proven safe and effective
in a pilot study conducted in 2006 where neurological outcomes were improved
in patients that received treatment (Shyu, Lin et al. 2006). These studies have
highlighted the therapeutic effects of GCSF, an effect that was confirmed by the
experiments discussed herein. Alike LIF, the presence of Akt Inhibitor IV blocked
GCSF protective effects. Also unexpected, the inclusion of the Akt inhibitor also
significantly elevated OL cell death as compared to OGD only controls. These
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results again identified the importance of the PI3/Akt survival pathway in the
mediation of OL survival.
Interestingly, a combination treatment of GCSF/LIF did not reduce cellular
cytotoxicity as a result of OGD compared to LIF treatment alone. There was no
synergistic or additive effect of combining the two soluble factors at the optimal
concentration of their individual doses. Because the Akt signal transduction
pathway is integral to cellular protection, these results suggest that this pathway
is maximally activated in OLs at the 200ng/ml concentration of LIF and GCSF.
Furthermore, these experiments showed that LIF is not the only soluble factor
secreted by HUCB cells, and that it is also not the only effective factor at blocking
OGD induced OL cell death.
Thus, we have highlighted two soluble factors secreted by HUCB cells that
promote oligoprotection via Akt and antioxidant enzyme activity. Following
optimization, both LIF and GCSF is just as efficacious as HUCB cells at
attenuating OGD induced OL cell death. These results therefore effectively
remedied the concerns associated with cell based therapy, and elevate these
factors as potential therapeutics.

Implications and Limitations
Here we have shown a viable use of cell based therapy by using HUCB
cells as potential treatment for ischemic stroke. First we identified that HUCB
cells protect not only the gray matter, but also the white matter following an
ischemic insult. With the identification of a defined pathway activated by HUCB,
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therapies can be developed to target this pathway and mimic these cells
protective effects. In addition to the finding that secreted soluble factors of HUCB
cells can have similar effects, the use of cells can be replaced by optimizing a
cocktail of soluble factors. This is important because of the current concerns with
the use of cell based therapy.
As depicted in Figure 1-3, from the experiments described here in, HUCB
cell treatment elicits therapeutic effect by secreting soluble factors. These factors
altered OL gene expression resulting in the upregulation of antioxidant,
myelinating and proliferative proteins such as Mog Mt3, Prdx and Uhmk1. The
secreted soluble factors activated Akt, where activated Akt as well as antioxidant
enzymes

reduced

ROS

production

and

oxidative

stress

by

inhibiting

mitochondrial dysfunction lead caspase induced apoptosis as a result of
ischemic. In a survival feedback loop, proteins such as Mt3 activates Akt and
upregulated other antioxidants such as heme oxygenase 1 (Hwang, Kim et al.
2008).
Soluble factors secreted by HUCB cells elicit respective effects on the
PI3/Akt pathway. In the experiments discussed, Akt appears to be the major
pathway utilized in OLs. As mentioned previously, soluble factors such as LIF
also activate STAT 3 and MAPK (Stahl, Boulton et al. 1994; Stahl, Farruggella et
al. 1995; Oh, Fujio et al. 1998). But these pathways appear to play no or minor
roles in oligoprotection. LIF is a pleiotropic factor, with receptors located
throughout the body. Thus, treatment with LIF could cause undesired side
effects. Overexpressed LIF in animals showed weight loss, overgrowth of
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medullary bone tissue in long bones, calcification of the liver heart and skeletal
muscle, thymus atrophy and the depletion of spermatogonia from male
seminiferous tubules of the testes (Metcalf and Gearing 1989; Metcalf and
Gearing 1989). The side effects mentioned above highlights chronic LIF
expression, in our treatment and disease model, single dose LIF was explored.
The aforementioned side effects therefore may be avoided but must be
considered nonetheless. Although this study has highlighted a specific cytokine
that has activity protecting the cerebral white matter, further investigation is
necessary to determine the safety of this drug. Timing of therapies is critical to
successfully treat a disease. Thus, implementation of LIF treatment in vivo, by
first addressing the dose response of LIF in animals subjected to MCAO,
measuring infarct volume and behavioral deficits following MCAO is to be
considered.
In addition, a long term assessment of LIF for treatment is essential. A
long term study would assess the permanence of LIF beneficial effects. Such
assessments could be made using reliable and time proven motor and memory
exams. Different variation of water maze, rotorod, and step test are typically used
to assess recovery following stroke.
Another important note is the fact that LIF is not the only potent factor
secreted by HUCB cells. As shown in this study, LIF neutralizing antibody does
not abolish the effect of HUCB cells. This finding was of no surprise primarily
because HUCB cells are known to secrete a vast number of soluble factors
(Newman, Willing et al. 2006; Neuhoff, Moers et al. 2007). This result implicates

189

that LIF is not relatively more potent than other secreted factors. Furthermore,
GCSF was also shown to be effective at similar concentration as LIF in blocking
stroke induced OL cell death. Thus, it would be important to optimize each
individual factor secreted by HUCB cells, and if necessary create an effective
cocktail that not only mimics the effect of HUCB cells, but improve upon the
effects discussed. Stroke is an acute but progressive disease, where the growth
factors, interleukins, metalloproteinase inhibitors and cytokines could be effective
at halting disease progression, but it is important to identify the time period in
which these factors could prove most efficacious.
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Figure 1. Mechanisms of OL Cell Death Following Ischemia and the Effect
of HUCB Cells. Figure depicts potential mechanisms of OL cell death as a result
of hypoxic ischemic injury and the effect of HUCB cell treatment. OL possess low
antioxidant content and operate at a high metabolic rate. Ischemia results in
energy depletion which reduces antioxidant content. Akt is dephosphorylated in
effect blocking its protective property. OL high metabolic and decrease
antioxidant store results in the accumulation of ROS/RNS resulting in oxidative
stress leading to mitochondrial disruption caspase activation and apoptosis.
HUCB cell treatment increase antioxidants Metallothionein 3 and Peroxiredoxin
4, this provides an increase in OL antioxidant stores thus attenuating the
accumulation of ROS. HUCB cells secretants increases Akt phosphorylation
reducing caspase activation and preventing apoptosis. It is important to note that
the mechanism proposed is not static, many of the processes mentioned
influences various areas of the cell death cascade.
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Figure 2. Mechanisms of HUCB Cell Protection of OLs. Figure depicts
potential mechanisms of OL protection as a result of HUCB cell treatment. HUCB
cells secrete soluble factors that activate the Akt survival pathway and enhance
protein expression. Akt phosphorylation reduces caspase activation and ROS
production thus preventing apoptosis. These soluble factors also increase gene
regulation and protein expression leading to cellular repair and detoxification.
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Figure 3. Mechanisms of LIF Protection of OLs Subjected to Ischemia. LIF
binds to receptor gp130 and LIFR which dimerizes and activates PI3/Akt
pathway. Akt activation increase antioxidant enzyme expression (Prdx4, Mt3)
and arrest mitochondrial dysfunction induced caspase 3 activation. Antioxidant
enzymes inhibit ROS production and caspase 3 activation thus blocking ischemia
induced apoptosis.
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